TNF-α signaling regulates the transcription of e-box driven clock genes by Petrzilka, Saskia
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2008
TNF-￿ signaling regulates the transcription of e-box driven clock genes
Petrzilka, Saskia
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-163812
Dissertation
Published Version
Originally published at:
Petrzilka, Saskia. TNF-￿ signaling regulates the transcription of e-box driven clock genes. 2008, University
of Zurich, Faculty of Science.
  
TNF-α Signaling Regulates the Transcription 
of E-box Driven Clock Genes 
 
 
Dissertation 
 
zur 
 
Erlangung der naturwissenschaftlichen Doktorwürde 
(Dr. sc. nat.) 
 
 
vorgelegt der 
 
Mathematisch-naturwissenschaftlichen Fakultät 
 
der 
 
Universität Zürich 
 
von 
 
Saskia Petrzilka 
 
von 
 
Winterthur ZH 
 
 
Promotionskomitee 
 
Prof. Dr. Adriano Fontana (Vorsitz und Leitung der Dissertation) 
 
Prof. Dr. Urs Greber 
 
Prof. Dr. Roger Nitsch 
 
 
Zürich, 2008 
  
TABLE OF CONTENTS 
 
 
1. ZUSAMMENFASSUNG 1 
2. SUMMARY 3 
3. INTRODUCTION 5 
3.1. CIRCADIAN RHYTHMS 5 
3.1.1. WHY HAVING A CIRCADIAN CLOCK? 5 
3.1.2. HISTORY OF CLOCK 5 
3.1.3. THE MAMMALIAN TIMEKEEPING SYSTEM 6 
3.1.4. THE INTRACELLULAR CLOCKWORK IN MAMMALS 9 
3.1.5. THE CLOCK OUTPUT 18 
3.1.6. WHAT HAPPENS WHEN THE CLOCK IS OUT OF TIME? 20 
 
3.2. INFLAMMATION 21 
3.2.1. CYTOKINE INDUCED SICKNESS BEHAVIOR 21 
3.2.2. TUMOR NECROSIS FACTOR-α SIGNALING 23 
 
3.3. AIM OF THE PROJECT 25 
4. RESULTS 26 
4.1. TNF-α SUPRESSES THE EXPRESSION OF CLOCK GENES BY 
INTERFERING WITH E-BOX MEDIATED TRANSCRIPTION 26 
 
4.2. CLOCK GENE MODULATION BY TNF-α DEPENDS ON CALCIUM AND P38 
MAP KINASE SIGNALING 55 
5. GENERAL DISCUSSION AND OUTLOOK 80 
6. REFERENCES 89 
7. ABBREVIATIONS 98 
8. ACKNOWLEDGMENTS 101 
9. CURRICULUM VITAE 102 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  1
1. ZUSAMMENFASSUNG 
Die biologische zirkadiane Uhr ist ein hochorganisiertes Zeitmessungssystem, 
welches zwischen allen Organismen konserviert ist. Die Tag- und Nachtzeit ist in 
jeder einzelnen Zelle genetisch festgehalten. Negative und positive 
Rückkoppelungsschlaufen der Genexpression und verschiedene post-translationelle 
Modifikationen der Uhrenproteine sind für einen ungefähren 24 Stunden Rhythmus 
verantwortlich. 
Das zirkadiane System hilft Individuen ihr Verhalten an die täglichen 
Umweltveränderungen anzupassen und physiologische wie auch metabolische 
Bedürfnisse auf spezifische Zeitfenster abzustimmen. Allerdings müssen diese 
Prozesse nicht nur auf die äusseren Bedingungen abgestimmt werden, sondern 
sollten flexibel bleiben und die Fähigkeit besitzen auf neue Ansprüche des Körpers, 
im Falle eines Angriffs durch Mikroben, zu antworten. 
Wie die Anpassung an die geophysikalische Zeit erfüllt wird, wurde schon gut 
untersucht. Lichtimpulse, welche auf die Retina treffen, werden über den 
retinohypothalamischen Gang an den suprachiasmatischen Nukleus (SCN) 
weitergeleitet. Durch intrazelluläre Signalwege, wie die Aktivierung von Kinasen und 
die Freigabe von Kalzium, wird der Uhren-Genexpressionszyklus gestartet. Daraufhin 
leitet der SCN seine Zeitinformation an die Peripherie weiter. Wie hingegen 
zirkadiane Uhren auf eine Immunantwort gegen Mikroben antworten, wurde bis jetzt 
nicht untersucht. Hinweise auf einen Zusammenhang zwischen dem Immunsystem 
und dem zirkadianen System ist daraus ersichtlich, dass sowohl die Produktion des 
pro-entzündlichen Zytokin Tumor Nekrose Faktor (TNF)-α bei einer Infektion als auch 
eine Dysregulation des zirkadianen Systems zu ähnlichen Symptomen führen wie z.B. 
Depressionen, Müdigkeit und Schlafstörungen.  
Das Ziel meiner Doktorarbeit war es, den Effekt von TNF-α auf die molekulare 
zirkadiane Uhr zu untersuchen und die zu Grunde liegenden intrazellulären 
Mechanismen zu erforschen. Dazu wurden Fibroblastenkulturen mit TNF-α stimuliert 
und die Expression der Uhrengene analysiert. Diese Gene waren stark inhibiert, 
jedoch ohne dass dessen Periodizität verändert wurde. Interessanterweise waren nur 
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E-box abhängige Gene betroffen. Der Einfluss dieser Kontroll-Elemente in dem TNF-α 
induzierten Inhibitionsmechanismus konnte zusätzlich mit Luziferase Reporter 
Versuchen bestätigt werden. Dabei wurden wildtyp und mutierte E-boxen verglichen. 
Im Bestreben die exakte Signalkaskade, welche zu den beobachteten Änderungen 
führt, zu definieren, wurden in den darauffolgenden Experimenten verschiedene 
Inhibitoren gegen intrazelluläre Signalkomponenten und Zellen mit spezifischen 
Gendefekten eingesetzt. Es konnte eine Rolle der zentralen negativen 
Uhrenregulatoren im E-box abhängigen Inhibitionsmechanismus ausgeschlossen 
werden. Der TNF-α Rezeptor 1 und intrazelluläres Kalzium stellten sich als wichtige 
Elemente in der Uhrengen Regulation heraus. Hingegen konnte ein Beitrag der 
wichtigsten TNF-α Signalwege NF-κB, AP-1, oder Kaspase, zumindest in der frühen 
Antwort, ausgeschlossen werden. Diese Resultate weisen darauf hin, dass Kalzium 
nicht nur in der SCN-Uhr, wo es umweltbedingte Zeitsignale übermittelt, eine 
Schlüsselrolle besitzt; sondern möglicherweise auch eine zentrale Komponente in der 
peripheren Uhr ist, wo es immunologische Veränderungen wahrnimmt.  
Es ist wahrscheinlich, dass der Körper im Falle einer Immunreaktion die 
physiologischen Prozesse zeitlich den neuen Bedingungen anpasst. Durch das 
Aufklären des genauen Mechanismus, mit welchem TNF-α die Uhr unterdrückt, wird 
es möglich sein in die Kaskade einzugreifen und somit spezifische Nebenwirkungen 
bei Patienten mit chronisch entzündlichen Krankheiten zu lindern. 
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2. SUMMARY 
The circadian clock is a highly organized timekeeping system that is well conserved 
across all organisms. The time of the day is marked genetically in every individual 
cell. Interlocked negative and positive gene expression feedback loops and several 
posttranslational modifications of clock proteins are responsible for an almost 24 
hour rhythm.  
The circadian system helps individuals to adapt their behavior to the daily 
environmental changes and adjusts physiological and metabolic needs to specific 
time windows. Sometimes, however, these processes not only have to be adapted to 
the environment but also need to be flexible and able to respond to new exigencies 
of the body when it is attacked by microbes. 
How the adaptation to the geophysical time is achieved has been the subject of 
many investigations already. Light inputs to the retina are transmitted to the 
suprachiasmatic nuclei (SCN) via the retinohypothalamic tract. By intracellular 
signaling, comprising kinase activation and calcium release, the clock gene 
expression cycle is launched. The SCN, in turn, further conveys its time information 
to the periphery. How circadian clocks are responding to an immune answer to 
microbes has not been investigated so far. A clear indication for cohesion between 
the immune and the circadian system is apparent because the production of the pro-
inflammatory cytokine tumor necrosis factor (TNF)-α upon infection and disruption of 
the circadian system both lead to similar symptoms such as depression, fatigue and 
sleep disturbances. 
The goal of my thesis was to investigate the effect of TNF-α on the molecular 
circadian clock and to further explore the intracellular mechanisms involved. 
Therefore, TNF-α was administered to a fibroblast cell culture and clock gene 
expression was found to be strongly dampened without affecting the periodicity. 
Interestingly, only E-box dependent genes were affected. The implication of these 
enhancer elements in the down regulation mechanism could be further confirmed by 
luciferase reporter assays comparing wild type to mutated E-boxes. In following 
experiments various blockers of intracellular signaling components and specific gene 
knock-out cells were used in the attempt to elucidate the precise signaling cascade 
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leading to the observed alterations. Thereby, a role for the central negative clock 
regulators in the E-box dependent inhibition mechanism could be excluded. The 
implication of the TNF-α receptor 1 and intracellular calcium were shown to be 
crucial for clock gene regulation by this cytokine. On the contrary, a contribution of 
the main TNF-α pathways NF-κB, AP-1 or caspase were clearly excluded at least in 
the early response. These results indicate that calcium is not only a key component 
of the SCN clock where it conveys environmental time signals, but possibly also plays 
a central role in the peripheral clock where it senses immunological changes. 
It is likely that the body timely readapts physiological processes in the case of an 
immune reaction. By elucidating the exact mechanism through which TNF-α 
dampens the clock it will be possible to intervene in the cascade to alleviate specific 
side symptoms of patients with chronic inflammatory diseases. 
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3. INTRODUCTION 
3.1. CIRCADIAN RHYTHMS 
3.1.1. Why having a circadian clock? 
All organisms studied so far have a system to tell the time of the day. This exists 
either in mammals, unicellular eukaryotes or prokaryotes, plants or fungi, even 
organisms that live deeply in caves and never see the sunlight. It is based on a 
circadian system: “circadian” derives from the Latin words circa and diem which 
together mean “about a day”. It is vitally important to be able to anticipate the 
coming of a certain time of a day. For example, bats living in a cave, which is not 
reached by sunlight, need to have a clock system to know when it is time to come 
out for eating and preys should hide before it is time for the predators to chase. Bees 
have to know which plants flower at what time and plants have to prepare their 
photo-system before sunrise so that they can start photosynthesis with the first 
sunbeam. These are all good reasons for organisms depending on the solar system, 
but what about the organisms that never are in contact with light? The idea is that a 
circadian system optimizes cellular physiology by distributing biochemical 
incompatible reactions to different times of the day, or why should glycogen 
synthesis and degradation happen at the same time? 
 
3.1.2. History of clock 
The dependency of physiological processes on day- or nighttime has been obvious to 
humans since we are able to think. Because of this self-evidence the underlying 
mechanisms remained unexplored for a long time. It seemed clear that these 
changes are passive reactions to the sunlight. The first scientist who took a closer 
look into it was the French astronomer Jean Jacques Ortous de Mairan. He noticed 
that when a mimosa plant was placed in constant darkness in a cupboard, the leaves 
would still be rigid during daytime and droop at nighttime. This clearly meant that 
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sunlight is not needed as a signal for the leaves to get rigid, thus mimosa have an 
endogenous clock (1). Henri Louis Duhamel du Monceau even went further and 
placed the mimosa in a dark mine where also temperature would stay constant. He 
could still observe the regular movement of the leaves meaning that the rhythm is 
temperature compensated. This was very hard to belief at this time because it was 
known that a rise in temperature would also accelerate biological processes. In fact it 
took many more years to accept that circadian clocks are really temperature 
compensated (2). The first hint for circadian rhythms in mammals came from 
temperature rhythms analysis in monkeys (3). A behavioral endogenous circadian 
rhythm in mammals was first reported by Curt Richter who monitored the locomotor 
activity of rats in constant darkness (4). Although the field of circadian rhythms was 
developing quickly by then, the first clock gene mutant was only discovered in 1971 
in Drosophila melanogaster (5). Since then, one highlight chased the other and even 
today great discoveries in the field are made at good pace. As mentioned by Gad 
Asher and Ueli Schibler “there is little risk that chronobiologists get bored within the 
next few years.” (6) 
 
3.1.3. The mammalian timekeeping system 
The overall circadian timing in mammals is organized in a hierarchical manner. As a 
central clock the suprachiasmatic nucleus (SCN) in the hypothalamic region serves as 
a pacemaker, it is self-sustained, meaning that it can keep circadian oscillation 
without the aid of external cues. This master clock is adjusted to geophysical time by 
light inputs received by the retina in the eye and transmitted to the SCN via the 
retino-hypothalamic tract. The SCN, in turn, can synchronize clocks in other brain 
regions and in the periphery via neuronal and humoral signals. The SCN is therefore 
a so called zeitgeber (German word for “time giver”). Synchronized slave oscillators 
then regulate local rhythms in physiology and behavior. The SCN can be seen as the 
time distributor (Figure 1). 
The SCN are paired nuclei located in the hypothalamic region right on top of the 
optic chiasm. Based on morphological differences the SCN can be subdivided in 
different parts, the two main ones being the “core” (ventrolateral) and the “shell” 
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(dorsomedial). The different regions of the SCN also have different pacemaking 
abilities, neuropeptide expression, response to environmental cues and rhythms to 
control. This is astonishing because the SCN is a very small structure consisting of 
not more than 20’000 cells in the mouse (7). 
Friedrich K. Stephan and Irving Zucker in 1972 were the first scientist who showed 
that the specific deletion of only the SCN leads to behavioral arrhythmicity in rats (8) 
and Robert Y. Moore and Victor B. Eichler showed in the same year that SCN deletion 
disrupts the circadian rhythm of adrenal corticosterone. At this time it was assumed 
that the rhythm translation to the periphery is achieved by neuronal signals and this 
was confirmed experimentally by Shin-Ichi Inouye seven years later (9). That not 
only neuronal signals but also humoral signals can confer rhythmicity to the 
periphery was shown in another very elegant experiment. Rea Silver and co-workers 
implanted encapsulated SCN into SCN-lesioned hamsters thereby preventing 
neuronal outgrowth but permitting humoral diffusion. The rhythmicity of these 
animals was restored showing that diffusible signals are also involved in circadian 
entrainment of the periphery (10). Moreover, they implanted the SCN of a hamster 
containing a mutation leading to a shorter period length. Now, the restored hamsters 
adopted the period length of the donor hamsters. This phenomena of period length 
transplantation was already observed earlier by Martin Ralph delivering the final 
proof that the SCN is indeed the central timekeeper (11). The question remained, 
though, whether the SCN only controls behavioral and physiological rhythms or also 
clock gene expression oscillations. This was answered by analyzing the expression of 
a core clock gene in peripheral organs of SCN lesioned rats. The circadian rhythm of 
this gene was disrupted in the periphery (12). Moreover the expression was also 
abolished in leukocytes, which are not innervated, showing that also the control of 
circadian gene expression in the periphery is in part accomplished by humoral signals 
(13). It is, though, unlikely that these factors released by the SCN exert their 
function directly in the periphery. SCN cells are too low in numbers for for the ability 
to produce enough proteins to reach a concentration high enough in body fluid. It is 
more probable that they act locally in larger adjacent brain regions which then in 
turn produce high amounts of signaling molecules. 
Several SCN derived diffusible molecules have been discovered since the year 2001: 
transforming growth factor (TGF)-α (14), prokineticin 2 (PK2) (15) and cardiotrophin 
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like cytokine (CLC) (16). All three molecules act as inhibitors of locomotion at 
different time windows leading to a robust and precise locomotor activity rhythm. 
Interestingly, no activators of locomotion have been found so far (Figure 1). 
Slave oscillators, either cells in peripheral organs or cells in a culture dish, can keep 
the 24h rhythm in gene expression for only a few days without external input (17, 
18). For a long time it was not clear whether this is due to a general dampening of 
the expression of core clock genes or if it is only a deception and in fact cells lose the 
synchrony and as a result are dephased. Two independent groups could show that in 
fact also peripheral oscillators are self-sustained (19, 20). The difference to the 
master clock is that there is no intercellular communication between individual cells 
to synchronize them. Therefore, and due to different period lengths of individual 
cells, a cell culture or peripheral organs dephase after a few days resulting in an 
apparent dampening of gene oscillation. 
The SCN, however, is not the only pacemaker for the periphery. This was first 
suspected when Dorothy Krieger reported that SCN lesioned rats that are given one 
meal per day still display circadian rhythms in body temperature and adrenal 
hormone secretion (21). Moreover it is possible to completely uncouple the 
peripheral clocks (e.g. the liver) from the SCN by restricted daytime feeding. 
Normally, laboratory rodents have the food available at any time. When animals are 
only given food during the day when they normally sleep, the circadian rhythm of 
peripheral organs is inverted by 180° whereas the phase of the SCN remains the 
same (22). Meaning that for peripheral oscillators feeding is the more dominant 
zeitgeber than the SCN. It is therefore possible that the SCN entrains the periphery 
by controlling rest-activity cycles and thereby also feeding. 
Body temperature, like scheduled feeding, has also been shown to serve as an 
indirect way of the SCN to synchronize the periphery as it is also controlled by sleep-
wake cycles. However this zeitgeber is not very strong and dominated by the 
restricted feeding zeitgeber (23) (Figure 1). 
As mentioned above, cells in an in vitro culture also possess a self-sustained clock, 
however this is only visible when the single cells are synchronized and oscillate in the 
same phase. High serum concentrations and multiple signals have been identified 
capable of resetting in vitro cultures. Sometimes the same signals are also used in 
vivo. One common feature in the synchronization of the cells by these signals is an 
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early induction of the central clock gene Period 1. The compounds comprise phorbol-
12-myristate-13-acetate (PMA), Calcimycin, forskolin, dexamethasone, 12-O-
Tetradecanoylphorbol-13-Acetat (TPA) and activate several different intracellular 
pathways such as Protein kinase (PK) A, PKC, cyclic adenosine monophosphate 
(cAMP), Ca2+, mitogen activated protein kinase (MAPK), glucocorticoid receptor, G-
protein-coupled receptors, glucose and retinoic acid receptor (18, 24-29). Some of 
these pathways, after a few steps, converge to a common one. The release of 
intracellular Ca2+ stores, the activation of PKC and the activation of G-protein-
coupled receptors result in the activation of MAPKs and probably in the 
phosphorylation of cAMP response element binding protein (CREB). CREB in turn 
binds to CAMP response elements (CRE) in the Per1 promoter resulting in induction 
of expression. It seems however that none of these pathways can fully account for 
the in vivo synchronization by the SCN or the in vitro synchronization by high serum 
concentration as blocking single signaling pathways doesn’t influence the resetting 
properties (18, 25).  
3.1.4. The intracellular clockwork in mammals  
The molecular clockwork mechanisms in the SCN, the peripheral tissues and cell lines 
in culture are known to be very similar. They not only consist of transcriptional-
translational feedback loops but are also very tightly regulated by post-translational 
modifications, such as phosphorylation, sumoylation and acetylation, chromatin 
remodeling and are also dependent on the metabolic state of the cell. 
Transcriptional‐translational feedback loops 
Most of the circadian genes were first discovered in Drosophila melanogaster by 
mutagenesis studies. While searching for the mammalian homologues it became 
clear that the mammalian clock is similarly organized. However, as expected the 
clockwork is also more complex, for one gene in D. melanogaster even two or three 
were found in mammals. It became also clear that there is a high probability of 
finding circadian genes that are exclusive for the mammalian system, meaning that it 
is important searching for these directly in mammals.  
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Every mammalian cell has an autonomous molecular oscillator consisting of several 
core clock proteins acting in interlocked positive and negative feedback loops. 
The two central elements of the positive loop are the basic helix-loop-helix (bHLH)- 
Period-Arnt-Single-minded (PAS) proteins BMAL1 (brain and muscle Arnt-like protein 
1) and CLOCK (circadian locomotor output cycles kaput). These proteins 
heterodimerize and bind to cis-acting enhancer elements called E-boxes in the 
promoters of several genes including members of the negative feedback loop, the 
Period (Per1 and Per2) and the Cryptochrome (Cry1 and Cry2) family genes. A third 
Period gene (Per3) exists, however, it is more considered as a clock output gene 
than a core clock protein. There are differential reports about whether CLOCK/BMAL1 
complexes remain bound to the DNA throughout the day or whether their E-box 
binding is circadian (30, 31). This might depend on the type of cells and the gene 
promoter. CRY and PER proteins in complex with casein kinase (CK) Iε and δ 
translocate back to the nucleus and inhibit the CLOCK/BMAL1 heterodimer and 
thereby also their own transcription. It appears that PER proteins are only modest 
inhibitors of CLOCK/BMAL1 activity, whereas CRY proteins are very efficient in 
inhibiting. This inhibition is most probably accomplished by stabilizing CLOCK and 
BMAL1 in an unphosphorylated and therefore inactive state (32). PER is important for 
recruiting CKI as CRY itself does not interact with the kinase. Moreover, CRY proteins 
are thought to mediate the nuclear import of the complex, although it has been 
reported that PER1 still reaches the nucleus in Cry deficient mice (27, 30). This may 
as well be cell type specific. In another regulatory loop, the orphan nuclear receptor 
Rev-Erbα is also activated via E-boxes by CLOCK/BMAL1. REV-ERBα, in turn, binds to 
the retinoic acid-related orphan receptor response (ROR) element in the Bmal1 
promoter to inhibit its transcription. While Bmal1 mRNA falls, PER and CRY proteins 
rise leading to Rev-erbα repression via CLOCK/BMAL1 and therefore to de-repression 
of Bmal1 (for review see (33)). Interestingly, simultaneously another nuclear orphan 
receptor, RORα, which contrarily activates Bmal1 transcription, is activated. RORα 
binds to the same ROR element and therefore competes with Rev-Erbα (34). 
Additionally PER2 serves as positive drive for Bmal1 as well. The mechanism is 
unclear but Bmal1 mRNA levels are strongly reduced and arrhythmic in Per2 mutant 
mice (35) (Figure 1). 
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Two other circadian proteins, differentiated embryo chondrocytes (DEC) 1 and DEC2, 
have been identified and analyzed in the last years. They can either directly bind to 
E-boxes and thereby act as inhibitors or in the presence of functional CLOCK/BMAL1 
act as co-activators depending on the context of the E-box binding complexes (36, 
37). They are thought to fine-tune the circadian cycles as the knock-down of both 
proteins only shows a mild circadian phenotype (38). 
Even more recently, in 2007, another core protein, clock interacting protein circadian 
(CIPC), meeting all criteria for being a negative regulator was discovered. Its 
expression is also driven by E-boxes and by forming a ternary complex with 
CLOCK/BMAL1, CIPC inhibits their transcriptional activity (39). 
A paralog of CLOCK, NPAS2, can replace CLOCK under some circumstances. Due to 
their overlapping function in the SCN, mice deficient in Clock or Npas2 are still 
rhythmic although with a shorter period length. Therefore, deleting both genes leads 
to complete arrhythmia in constant darkness (40).  Because peripheral clocks, in 
contrast to the central clock, do no longer oscillate in the absence of the Clock gene, 
it is clear that NPAS2 can only maintain rhythmicity in the SCN (41). 
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Fig.1: The mammalian timekeeping system (inspired by (42) and (43)) 
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Chromatin remodeling 
Chromatin remodeling is a well known and very important mechanism of 
transcriptional control. Histones can be modified with acetyl, methyl, phosphor, sumo 
or ubiquitin groups. It is not surprising that modifying histones also plays a dominant 
role in circadian transcriptional control. 
 
Acetylation 
The first hint of a rhythmical acetylation of histones was delivered by Jean-Pierre 
Etchegaray in 2003. He demonstrated that histones H3, but not H4, in the Per1 and 
Per2 promoters are acetylated with a circadian pattern resulting in transcriptional 
activation. The histone acetyl transferase (HAT) that accounts for this acetylation is 
p300, which he found to directly bind to CLOCK/BMAL1 heterodimers (44). 
A few years later Jürgen Ripperger and Ueli Schibler very nicely showed that at the 
promoter of the clock output gene D-element binding protein (Dbp) the chromatin 
structure changes from a condensed to an uncondensed state in a circadian manner. 
This is achieved by a rhythmic change in histone modification. In that sense they 
showed that histone H3 acetylation at Lys 9 and the tri-methylation at Lys4 is 
circadian, and as expected the di-methylation of histone H3 at Lys 9 and HP1α 
binding to the DNA are exactly antiphasic (31). 
Only two months past before Masao Doi made the great discovery that the central 
clock component CLOCK is not only a “boring” transcription factor but actually also 
an enzyme, namely a HAT. CLOCK is therefore capable of acetylating histones and 
this function is enhanced by its partner BMAL1 (45). 
For Deacetylation it seems that the NAD+ dependent histone deacetylase (HDAC) 
sirtuin (SIRT) 1 is responsible. SIRT1 can form a complex with CLOCK/BMAL1 and 
deacetylate histone H3 (46). An involvement of SIRT1 mediated inhibition was 
already assumed earlier when it was found that the clock protein DEC2 associates 
with SIRT1 via the bHLH domain (37). DEC2, as described above, is a negative 
regulator that binds directly to E-boxes. It is therefore plausible that this inhibition is 
mediated via histone deacetylation by SIRT1.  
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Phosphorylation 
Of all histone modifications, phosphorylation has the privilege to be directly linked to 
intracellular signaling pathways. Meaning that a kinase activated by an extracellular 
signal can directly contribute to chromatin remodeling. Additionally, histone 
phosphorylation can lead to an enhanced HAT-dependent histone acetylation (47). 
In relation with circadian rhythms there is one interesting report revealing that a light 
pulse induces histone phosphorylation in the SCN in parallel with CREB 
phosphorylation and therewith Per1 induction. The light induced kinases responsible 
for histone phosphorylation remain to be identified, however kinases of the AGC 
family are suspected (48). 
 
Redox 
By chance the group of Steven McKnight recognized that the ratio of reduced to 
oxidized nicotinamid adenine dinucleotide or the phosphorylated cofactor (NAD(P)H 
and NAD(P) respectively) has a great influence on the DNA binding of CLOCK and 
NPAS2. They showed that the heterodimeric interaction with BMAL1 is greatly 
stimulated by NAD(P)H. In contrast, the oxidized form even inhibited the interaction, 
leading to BMAL1 homodimers binding to Ebox sequences. These homodimers are 
incapable of activating transcription. Furthermore they report lactate dehydrogenase 
(LDH), an enzyme that catalyzes the reduction of pyruvate to lactate using the NADH 
cofactor, to be a direct target of CLOCK/BMAL1. Because LDH itself can also 
influence cellular redox potential and with this the DNA-binding abilities of its 
activator it can also be regarded as a clock component contributing to an additional 
negative loop (49). 
 
Post‐translational modifications 
Transcriptional and translational feedback loops solely would not result in a 24 hours 
but rather in a much shorter rhythm of only a few hours. Although translational 
control may also contribute to a time delay, post-translational modifications have 
been the most well studied mechanisms for post-transcriptional control. 
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Many of the core clock genes are expressed circadian with the exception of Clock, 
which in many tissues does not cycle. However, when the cycling is destroyed by 
over-expression of these proteins, it does not eliminate the overt rhythm (50). This is 
due to the post-translational control leading to regulated destruction or activity of 
clock proteins (51). 
 
Phosphorylation 
Phosphorylation of clock proteins can have differential effects. It can alter subcellular 
location, activity, DNA-binding affinity and last but not least it can lead to protein 
ubiquitination and therefore degradation. It is therefore not surprising that most of 
the core clock proteins are phosphorylated with a circadian pattern (30).There is 
often no general statement possible that phosphorylation of a certain protein leads to 
a specific change because it depends strongly on which residues are phosphorylated 
by which kinase in what cell type. There is a set of kinases that have been shown to 
be involved in circadian rhythm generation. 
CKI: The most important kinases involved in circadian rhythms are CKIε and CKIδ. A 
mutation of the CKIε gene in hamsters leads to period shortening of 4h. With the 
exception of Clock and Bmal1 deletion which lead to arrhythmia the mutation or 
deletion of other core clock genes leads at maximum to a shortening or lengthening 
of 1.5h (52). 
One important role of CKI is the control of protein degradation. The two negative 
regulators PER1 and PER2 are both phosphorylated by CKIε. Thereby a SKP1-Cullin1-
F-box protein (SCF) E3 ubiquitin ligase containing β-transducin repeat containing 
protein (βTrCP) as an F-box protein is recruited. This subsequently leads to 
ubiquitinylation and degradation of these proteins by the proteasome pathway (53, 
54). The CRY proteins are degraded by another SCF E3 ubiquitin ligase that contains 
FBXL3 as an F-box protein (55-57). Although it has not yet been shown that post-
translational modification of CRY proteins are necessary for FBXL3 binding, it is very 
probable. CKI and also glycogen synthase kinase (GSK) 3β can phosphorylate CRY, 
and the function of phosphorylated CRY is unknown so far (58, 59).  
The data about the influence of CKI on subcellular localization of PER is confusing. 
Depending on the cell type, phosphorylation of PER1 can lead to translocation into 
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the nucleus or into the cytoplasm (60, 61). CKI mediated phosphorylation of PER2, 
though, does not influence its subcellular localization. 
CKI also positively regulates the activity of BMAL1 but not of CLOCK (58). 
Intriguingly, CKI is constitutively expressed meaning that some other protein serve 
as regulators of the kinase. So far only one protein phosphatase (PP) could be 
identified to regulate CKI, namely PP5 (62). Although PP1, PP2A and PP2B are able 
to activate CKI in vitro, evidences that they are also physiological activators are 
missing. The role of phosphatases in the clock is therefore likely to be complex, 
because they may be involved in stimulating CKI activity and/or act in direct 
opposition to clock kinases by dephosphorylating PER proteins (see next chapter) 
 
GSK-3β: As mentioned above GSK-3β also plays a major role in the circadian rhythm. 
The activity of this kinase is circadian in vivo in the SCN and in vitro in synchronized 
NIH 3T3. Inhibiting GSK-3β leads to a phase delay. It was shown to interact with and 
phosphorylate PER2 leading to nuclear translocation (63). Additionally it can also 
phosphorylate and thereby stabilize REV-ERBα (64) and finally, as already mentioned 
above, GSK-3β phosphorylates CRY2, targeting it to degradation when exiting the 
nucleus (59). GSK-3β itself is regulated  by an inhibitory phosphorylation at a Ser 
residue, resulting in circadian activity cycles of this kinase (59) 
MAPK and other kinases: The MAPK ERK and MEK have been shown to be activated 
in a circadian pattern in the chick pineal gland and the bullfrog retina, and that the 
inhibition of these kinases leads to a phase shift (65, 66). The same group describing 
the phase shift showed two years later that ERK phosphorylates BMAL1 and leads to 
inhibition of its activity. Three residues are phosphorylated (Ser-527/Thr-534/Ser-
599) by the MAPK. Interestingly these residues are highly conserved in BMAL1 across 
vertebrates, raising the possibility that the same mechanism may take place in 
mammals (67). This is in contrast to phosphorylation of BMAL1 by CKI leading to an 
induction of activity, but this may be due to different phospho-acceptors of the two 
kinases. Together they may tightly regulate the activity status of BMAL1.  
In mammals the MAPK p38 and ERK and the calcium/calmodulin dependent kinase II 
have been implicated in clock protein phosphorylation. However strong evidences for 
having a dominant role in the regulation of mammalian clocks are missing. Recently, 
PKC was described to phosphorylate CLOCK proteins, targeting it to the nucleus (68). 
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Obviously when kinases are active in some processes, phosphatases cannot be far 
away as well. Nevertheless, only little investigations about their role in circadian 
clocks have been conducted in mammals so far. 
There is one study showing that PP1 binds to and dephosphorylates PER2, thereby 
opposing the effect of CKI. Hence, the protein is stabilized and prevented from 
degradation by the proteasome pathway (69). 
Another group could show that PP5 indirectly regulate PER phosphorylation. They 
demonstrate the interaction of PP5 with CKI on one hand and with CRY proteins on 
the other hand. By binding to CKI it activates the kinase and therefore indirectly 
regulates the phosphorylation of PER. When CRY2 is added to this complex the PP5 
mediated activation of CKI is inhibited. Thus CRY2 indirectly controls PER and maybe 
also its own phosphorylation (70). 
Despite many reports about a role of PP2A in Neurospora crassa and D. 
melanogaster circadian control, until today no implications in the mammalian system 
have been found. 
 
Sumoylation 
Sumoylation is a small protein modification added by Small ubiquitin related modifier 
(SUMO) proteins. Like ubiquitin ligases, SUMO proteins can form polysumoylation 
chains. This modification, similar to phosphorylation, can then influence protein 
stability, localization and protein-protein interactions (For review see (71)). The first 
report about a role for sumoylation was provided by the group of Paolo Sassone-
Corsi. They found that the core clock protein BMAL1 is sumoylated by SUMO1 with a 
circadian pattern and in a CLOCK dependent manner. BMAL1 protein mutated at the 
sumoylation site no longer displays circadian rhythmicity and was more abundant 
indicating that the modification destabilizes BMAL1 (72). A few weeks ago another 
group confirmed the sumoylation and hence the stabilization of BMAL1, however 
they claim that this is more likely to be achieved by SUMO 2/3 than SUMO1. 
Additionally they deliver evidences that after sumoylation BMAL1 is targeted to the 
nuclear body of the nucleus. Ultimately, BMAL1 is ubiquitinated, transactivated and 
transmitted to proteasomal degradation (73). This modification adds another degree 
to BMAL1 regulation. Probably it is a matter of time before sumoylation modifications 
are found on other clock proteins. 
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Acetylation 
Very recently it was shown that CLOCK with its HAT activity is not only implicated in 
chromatin remodeling but also in acetylation core clock proteins. Indeed it was 
shown that BMAL1 is acetylated rhythmically with a peak in acetylation paralleling 
the downregulation of CLOCK/BMAL1 controlled genes. The acetylation is achieved 
by CLOCK and the repression is promoted by a facilitated recruitment of CRY1 (74). 
On the opposite SIRT1 is responsible for rhythmic deacetylation of BMAL1 (46).  
That PER2 is also rhythmically acetylated was evidenced this year. The responsible 
acetyl transferase has not been discovered yet, but CLOCK and/or p300 are good 
candidates for it. What is clear so far is that SIRT1 is responsible for PER2 
deacetylation and that this deacetylation leads to destabilization and degradation of 
the protein. It is hypothesized that PER2 is acetylated and ubiqutinated at the same 
residue so that SIRT1 would free the Lys to be ubiqutinated by removing the acetyl 
residue (75) 
 
In my opinion in the next years research will come up with many other clock proteins 
discovered to be modified in many ways. Probably also other kind of modifications 
will be found, such as methylation, hydroxylation or glycosylation which have not 
been looked at so far. 
3.1.5. The clock output 
Once the slave oscillators are synchronized by the SCN, the local rhythms are 
entrained as well. It is thought that this is attained through first order clock 
controlled genes (CCGs). There is only a few rhythmic genes that are directly 
controlled by CLOCK/BMAL1 and regarded as clock output even though, all in all, 
microarray analysis of gene expression in different cell lines and mouse tissues have 
revealed that about 2-10% of the genes are in fact expressed with a circadian 
pattern, indicating that many of them are controlled indirectly. Moreover the 
expression is very tissue specific as only about 5% of the genes overlap between 
tissues. The first order CCGs are the direct way by which the core oscillation can be 
transduced to regulate downstream events in peripheral tissues, they are the 
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transcription factors controlling other cell specific transcription factors or enzymes 
(76-79). 
The SCN output factors TGF-α, PK2 and CLC are considered to be CCGs. The proline 
and acidic amino acid-rich basic leucine zipper (PAR-bZIP) family member D-element 
binding protein is a prototype of a CCG. This PAR-bZip transcription factor has been 
involved in many aspects of metabolism of glucose (80), bile acid (81), or toxic 
compounds contained in food (82, 83). Its closely related genes thyrotroph 
embryonic factor (Tef) and hepatic leukemia factor (Hlf), although their direct 
regulation through CLOCK/BMAL1 has not been investigated so far, also play an 
important role in circadian physiological function. As mice lacking one or two of these 
genes only show mild phenotypes such as sleep disturbances and slight deviations in 
period length, it is thought that their functions are partly redundant (84, 85). When 
all three genes are knocked out, animals die of lethal audiogenic and spontaneous 
epileptic seizures (86). It is hypothesized that this is due to disequilibrium in 
neurotransmitter homeostasis. It was observed that these mice have a deficiency in 
pyridoxal kinase (Pdxk) expression. PDXK is involved in the vitamin B6 metabolism, 
turning it into its active form pyridoxal phosphate (PLP). PLP is a co-factor for many 
enzymes, among which many are involved in neurotransmitter metabolism (86). If 
the mice survive until the third month of age they no longer succumb to epileptic 
seizures but still exhibit high morbidity, rapid aging and die within one year. It is 
speculated that early aging and premature mortality arises from metabolic disorders 
caused by the absence of the PAR-bZIP proteins. In line with this, it has recently 
been shown that the triple knockout mice show a high deficiency in xenobiotic 
detoxification. Microarray data revealed that particularly the expression of genes 
involved in the detoxifying system is disrupted. It is nevertheless not clear whether 
these genes are direct targets of the PAR-bZIP transcription factors; anyway many of 
the affected genes harbor promoter sequences with strong homologies to PAR-bZIP-
responsive elements (87). 
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3.1.6. What happens when the clock is out of time? 
While in mice the different effects of single clock gene deletions or mutations are 
well known and have been analyzed in details, only a few consequences of such 
alterations have been identified in the human clock. 
One of the most common is the familial advanced sleep phase syndrome (FASPS). 
People affected by FASPS go to bed and wake up about four hours earlier than the 
average. The disease is associated with a hypophosphorylated PER2 protein. Two 
mutations that lead to hypophosphoralytion have been found in FASPS pedigrees. 
The first one is a miss-sense mutation in the Per2 gene within the binding site of 
CKIε and the second one is a mutation in the kinase itself leading to reduced 
enzymatic activity (88, 89). In the mirror case, known as delayed sleep phase 
syndrome people go to bed and wake up later than normal. A mutation in an auto-
phosphorylation site of CKIε has been found to generate a kinase that is 
approximately 1.8 fold more active (90). 
We all feel less active and motivated in wintertime. For some people it can even end 
up in depressions. These persons have a seasonal affective disorder (SAD). In recent 
years SAD could be associated with single nucleotide polymorphism (SNP) variants in 
Per2, Bmal1 and Npas2 with additive effects from combined risk genotypes (91). 
Other SNP could be associated with alcohol consumption (92). 
The molecular clock is not only altered by clock gene mutations but can also be 
influenced by environmental changes. This is most apparently experienced when 
travelling around the world and suffering from jetlag or when working during night 
time and trying to sleep during day time. In both of these cases people are active 
and eat at a time that is not in concert with the internal clock. Indeed night-shift 
workers have poorer daytime sleep and reduced night time alertness and 
performance. Prominent health problems among shift workers include sleep disorders 
(which can become chronic), gastrointestinal disease, increased incidence of 
cardiovascular disease and possibly an increase in late-onset diabetes (93-95). At 
least for jetlagged persons this is only a temporary state, as the clock can shift 
approximately one hour per day and thereby synchronize to the new external 
environment. In contrast the shift-worker’s clock is constantly in conflict with the 
environment. 
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Generally, a consequence of our today’s lifestyle is already a disruption of the 
circadian rhythm, which not only results in sleep disturbances and depressions but 
has also been correlated to a higher susceptibility to cancer, especially breast cancer 
(96). Incidence of breast cancer in women increases proportionally with the amount 
spent working at night (97). Indeed, the circadian clock shares a number of 
conceptual and molecular similarities with the cell cycle (98). It has been shown that 
CLOCK/BMAL1 directly regulate a set of cell cycle genes such as Wee1, c-myc and 
Cyclin D1 (99, 100). Moreover PER1 and PER2 are potent tumor suppressors in mice. 
Mice devoid of PER2 are more prone to malignant lymphomas (100). On the 
contrary, the ectopic expression of Per2 results in growth inhibition and cell cycle 
arrest (101). These are all links between the clock and cancer, however the 
molecular mechanism is not understood so far. 
 
3.2. INFLAMMATION 
The response to a microbial pathogen can roughly be split into two phases. The first, 
the innate immune response is rapid and destructive and somewhat unspecific and 
self-limiting. The second, the adaptive response, is activated by the inflammation but 
takes a few days to be effective, it is very specific and includes memory function. 
Cells involved in the innate immunity use invariant receptors called Toll-like receptors 
(TLRs) to detect and signal the occurrence of microbial infections (102, 103). By 
binding to TLRs, pathogens induce a highly coordinated process, which is 
commenced by the secretion of pro-inflammatory cytokines such as tumor-necrosis 
factor alpha (TNF-α), Interleukin (IL)-1beta, IL-6 and Interferons (IFNs). These 
cytokines alert and recruit other cells of the immune system such as neutrophils, 
macrophages and dendritic cells, which then help initiate the adaptive immune 
response. A hallmark of inflammation is the occurrence of fever, fatigue and weight 
loss (104). 
3.2.1. Cytokine induced sickness behavior 
Everyone who has experienced a bacterial or viral infection knows how it feels to be 
sick. We then feel tired, listless and irritable, loose appetite and interest in social 
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activities, have fever and nausea and our sleep is often fragmented. Collectively 
these symptoms are referred to as “sickness behavior”. These changes make 
perfectly sense; they are a highly organized strategy of the organism to fight 
infections and contribute to the recovery. The organism, thereby, prevents the 
occurrence of those activities that are metabolically expensive and favoring those 
that decrease heat loss and increase heat production. However, these symptoms are 
also well known to have a negative impact on the quality of life of patients with 
chronic inflammatory disorders. 
As soon as the sequences of the pro-inflammatory cytokines IL-1, IFN-α and TNF-α 
were identified and the proteins expressed in recombinant forms, they were tested in 
patients with a variety of cancers or, in the case of INF-α, with infectious diseases. 
The systemic administration of these cytokines was soon recognized to give the 
same side effects as after an infection; they lead to sickness behavior. 
The cytokines produced upon an infection or injected in the periphery also act on the 
brain. There are several pathways of communication. The fastest one involves 
afferent nerves such as the vagal nerves that are activated by the locally produced 
cytokines. Animals injected with LPS, IL-1 or TNF-α intraperitoneally show the full 
spectrum of sickness behavior, however upon vagotomy these symptoms are 
reduced or disappear (105-107). It is thought that the stimulation of the vagal 
nerves leads to IL-1 and subsequently also TNF-α and prostaglandin of type E 
expression in the brain, which in turn act on specific neural substrates to induce 
sickness behavior (108). Vagotomy, however has no effects when cytokines are 
injected subcutaneous or intravenously (109, 110) indicating that other routes are 
employed to communicate with the brain. Indeed, a second slower pathway exists. 
Macrophage-like cells residing in the circumventricular organs and the choroid 
plexus, near the blood brain barrier, express TLRs and cytokine receptors and can 
thereby respond to circulating pathogens or cytokines (111, 112). The result of both 
pathways is the production of pro-inflammatory cytokines by microglial cells in the 
brain. Presumably, activation of the neural pathway sensitizes target brain structures 
for the production and action of cytokines diffusing from the circumvetricular organs 
and the choroid plexus. (113-115). 
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3.2.2. Tumor necrosis factor‐α signaling 
Already more than one century ago it was discovered that antitumoral agents are 
released after a pathogen infection (116). This knowledge led to the idea to cure 
tumors by the use of bacterial extracts (117). It needed another 70 years to realize 
that the effect of bacterial extracts is not direct but mediated by a factor that was 
designated as TNF-α (118). After another 20 years, TNF-α was cloned and analyzed. 
The structure and function revealed a close homology to lymphotoxin-α (119). 
Almost simultaneously and independently cachectin was discovered as a mediator of 
cachexia in patients infected with trypanosomes. Immediately, it became clear that 
TNF-α and cachectin are in fact one and the same molecule (120).  
TNF-α forms homotrimers and is primarily produced as a transmembrane protein. 
This membrane-integrated form can be cleaved by the metalloprotease TNF-α 
converting enzyme (TACE) to release the likewise homotrimeric soluble TNF-α (121, 
122). 
Two receptors forward the signal into the cell: TNF receptor (TNFR) 1 and TNFR2. 
Whereas TNFR1 is constitutively expressed, TNFR2 is highly regulated and 
preferentially found on endothelial cells and cells of the immune system. Additionally 
TNFR2 can only be fully activated by membrane bound TNF-α (123). The 
extracellular domain of both receptors can be cleaved resulting in fragments with 
neutralizing potential (124).  
TNF-α binds to the already pre-assembled receptor. Interestingly neither receptor 
contains any enzymatic activity. Instead, the intracellular parts harbor protein 
interacting domains. 
By TNF-α binding to TNFR1 the inhibitory protein silencer of death domain (SODD) is 
released from the intracellular tail and replaced by the adaptor protein TNF receptor- 
associated death domain (TRADD). The three adaptor proteins receptor-interacting 
protein (RIP), TNFR-associated factor 2 (TRAF2) and Fas-associated death domain 
(FADD) are recruited as well and are responsible of initiating the intracellular 
signaling. The first event in the apoptosis cascade is recruitment of caspase 8 to 
FADD where it becomes activated. TRAF2 activates extracellular signal-regulated 
kinase kinase kinase 1 (MEKK1) or apoptosis stimulated kinase 1 (ASK1), activating a 
kinase cascade which will result in the activation of c-jun NH2-terminal kinase (JNK). 
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The phosphorylation and heterodimerization of c-jun to form the transcription factor 
activator protein-1 (AP-1) leads to the transcription of proteins involved in 
proliferation, differentiation and induction, as well as prevention of apoptosis (125). 
Besides JNK, TRAF2, MEKK1 and ASK1 together with RIP have also been implicated 
in the activation of p38 MAPK (126). The activation of both kinases is only transient, 
but show prolonged action under apoptotic conditions. The p38 MAPK signaling 
pathway is a mediator of inflammatory processes by inducing the production of IL-1 
and IL-6. The mechanism, however, is not known. The best studied arm of TNFR1 
signaling is the nuclear factor kappa B (NF-κB) pathway, which involves the adaptor 
protein RIP. In quiescent cells NF-κB is retained in the cytoplasm by the inhibitor of 
κB (IκB). Upon stimulation, the multiprotein IκB kinase (IKK) complex is recruited to 
the receptor, activated in a RIP dependent manner and then phosphorylates IκB. IKK 
consists of two catalytic subunits, IKKα and IKKβ, and a regulatory subunit, NF-κB 
essential modulator (NEMO). Upon phosphorylation IκB is ubiquitinated and 
degraded allowing NF-κB to enter the nucleus. There it binds to NF-κB site and 
activates the transcription of anti-apoptotic as well as pro-inflammatory proteins.  
The signaling pathway of TNFR2 is less clear. In contrast to TNFR1, TNFR2 lacks an 
intracellular death domain (DD). It instead can directly recruit TRAF2 and activate 
the NF-κB pathway. The activation of TNFR2, unlike TNFR1, may promote cell 
activation, proliferation and migration. However, TNFR2, under some circumstances, 
may contribute to TNFR1 signaling. At low TNF-α concentrations TNFR2 passes its 
ligand to TNFR1 (127, 128). 
TNF-α can have both harmful and beneficial activities. The transmembrane 
expression indicates that this molecule is meant to act locally. However, under non-
physiological conditions, TNF-α is released and acts on various cell types to mediate 
its systemic effects. Hence, neutralizing TNF-α can be helpful to cure some diseases 
but serious harmful side effects have been observed as well. These comprise 
tuberculosis infection, demyelinating syndromes and systemic lupus erythaematosus-
like reactions (129). (130-132). 
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3.3. AIM OF THE PROJECT 
The symptoms of sickness behavior, such as fatigue, reduced appetite, sleep 
disturbances, provoked by cytokines have a negative impact on patients with chronic 
inflammatory disorders but not much can be done to alleviate these symptoms. The 
mechanisms by which the periphery talks to the brain to induce sickness behavior 
have only been explored in recent years and our understanding of communication 
pathways is not complete. Sickness behavior including less activity, fever, listless 
(kind of depression) and also less eating, has been described to be directly 
transduced to the brain from an infection in the periphery by the vagal nerves or 
humoral signals. We, however, think that cytokines not only talk to the brain by the 
two known pathways but also act on peripheral organs to influence the circadian 
clock and thereby alter metabolism and activity. These alterations may have an 
indirect impact on the brain resulting in alterations of rest-activity cycles, feeding 
behavior and temperature.  
As mentioned above the central and peripheral clocks can be reset by a variety of 
different chemical compounds and hormones. Several studies report that also some 
cytokines can modulate the clock: IL-6 (133), IFN-α (134, 135), IFN-γ (136), as well 
as the hormone Prostaglandin E2 (137). It is important to know the impact of 
cytokines on the circadian system and to elucidate the pathways by which cytokines 
modulate the molecular clock. Only that way it will be possible in the future to 
intervene in the cascade to alleviate specific side symptoms without interfering with 
the entire immunological process. 
So far, no reports can be found about the pro-inflammatory cytokine TNF-α, although 
it plays a pivotal role in the cytokine induced sickness behavior. Therefore, the aim of 
my thesis was to observe the effects of TNF-α on the molecular clock in an in-vitro 
system with a fibroblast cell line. Using several compounds interfering with different 
arms of the TNFR1 and TNFR2 signaling pathway, our ambition was to define the 
route leading to clock gene expression variations. 
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4. RESULTS 
4.1.  TNF‐α  SUPRESSES  THE  EXPRESSION  OF  CLOCK  GENES  BY 
INTERFERING WITH E‐BOX MEDIATED TRANSCRIPTION 
 
Cavadini, G., Petrzilka, S., Kohler, P., Jud, C., Tobler, I., Birchler, T. & Fontana, A. 
(2007) Proc Natl Acad Sci U S A 104, 12843-8 
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Summary 
Production of TNF-α and IL-1 in infectious and autoimmune diseases is 
associated with fever, fatigue and sleep disturbances which are 
collectively referred to as sickness behavior syndrome. In mice TNF-α and 
IL-1 increase non-rapid eye movement sleep. Because clock genes 
regulate the circadian rhythm and thereby locomotor activity and may 
alter sleep architecture we assessed the influence of TNF-α on the 
circadian timing system. TNF-α is shown here to suppress the expression 
of the PAR bZip clock-controlled genes Dbp, Tef and Hlf and of the period 
genes Per1, Per2, and Per3 in fibroblasts in vitro and in vivo in the liver of 
mice infused with the cytokine. The effect of TNF-α on clock genes is 
shared by IL-1β, but not by IFN-α, and IL-6. Furthermore, TNF-α interferes 
with the expression of Dbp in the suprachiasmatic nucleus and causes 
prolonged rest periods in the dark when mice show spontaneous 
locomotor activity. Using clock reporter genes TNF-α is found here to 
inhibit CLOCK-BMAL1 induced activation of E-box regulatory elements-
dependent clock gene promoters. We suggest that the increase of TNF-α 
and IL-1β, as seen in infectious and autoimmune diseases, impairs clock 
gene functions and causes fatigue. 
 
Introduction 
In microbial infections, host defense mechanisms activate the innate and adaptive 
arms of the immune response. Microbial recognition by Toll-like receptors (TLR) 
expressed by macrophages and dendritic cells leads to the activation of signal 
transduction pathways with induction of various genes including IL-1, TNF-α, IL-6, 
and IFN-α/β (1-3). These cytokines mediate the acute–phase response, which is a 
systemic generalized reaction characterized by fever, fatigue, and weight loss, an 
increase in the number of neutrophils, and the induction of synthesis of acute-phase 
proteins in the liver with increased haptoglobin, antiproteases, complement 
  29
components, fibrinogen, ceruloplasmin, and ferritin in the blood (4). An acute phase 
response with a dose-dependent state of lethargy and severe fatigue has been 
described in cancer patients treated with TNF-α (5). A link between production of 
TNF-α and daytime fatigue has also been suggested in rheumatoid arthritis (RA) and 
in the obstruction sleep apnea syndrome (OSAS). Inhibition of TNF-α by soluble TNF-
receptor p75 improves disabling fatigue in patients with RA (6). A TNF-α-308 (A-G) 
single-nucleotide polymorphism and elevated TNF-α serum levels have been 
described in OSAS (7, 8). Moreover, neutralization of TNF-α reduces daytime 
sleepiness in sleep apneics (9). Direct effects of TNF-α on spontaneous sleep are 
also shown in animal studies. i.v., i.p., or intracerebroventricular injections of TNF-α 
or IL-1 enhance nonrapid-eye movement (NREM) sleep (for reviews see refs. 10 and 
11). This increase in NREM sleep is independent of the fever-inducing capacity of 
these cytokines (12). Although there is good evidence for TNF-α and IL-1 as 
mediators of altered sleep-wake behavior, the underlying mechanisms remain 
elusive. 
The regulation of sleep depends on a circadian control and a homeostatic drive (13, 
14). The circadian influence is provided by the suprachiasmatic nuclei (SCN) of the 
hypothalamus being entrained by light stimuli to the environment. This self-
sustaining circadian pacemaker uses a molecular mechanism similar to the one used 
in subsidiary oscillators present in any type of cell in the organism. The molecular 
clockwork involves the transcriptional repressor genes Per1, Per2, Cry1, and Cry2, as 
well as the transcriptional activators Bmal1 and Clock. The heterodimerized 
transcription factor BMAL1:CLOCK activates Per and Cry gene transcription by 
binding to E-box motives in their promoters. PER and CRY proteins inhibit 
BMAL1:CLOCK complexes, thereby inhibiting their own gene expression. This 
feedback-loop mechanism generates circadian oscillations of Per and Cry expression. 
The same positive and negative regulatory components also govern the rhythmic 
expression of the nuclear orphan receptor Rev-Erbα, which in turn represses the 
transcription of Bmal1 through direct binding to a REV-ERBα response element in the 
Bmal1 promoter. Thereby, REV-ERBα interconnects the cyclic expression of positive- 
and negative-loop members (for reviews, see refs. 15 and 16). The targeted 
inactivation of Bmal1 showed that this gene is indispensable for the maintenance of 
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circadian functions (17). Clock-deficient mice show robust circadian patterns of 
locomotor activity with period lengths shortened by only twenty minutes; Dbp mRNA 
rhythm, however, was severely blunted in both the SCN and the liver (18). The 
deletion of the clock-controlled genes (CCG) PAR bZip transcription factors Dbp, Tef, 
and Hlf only moderately affects the circadian clock but leads to pronounced 
disturbances of locomotor activity. In the present study, our objective was to 
examine (i) whether and how TNF-α influences the circadian timing system and 
modulates the expression of clock genes and CCGs, and (ii) whether TNF-α affects 
locomotor activity, rest time, and periodicity in mice. 
 
Results 
Suppressed  expression  of  clock  genes  in  TNF‐α  treated  synchronized 
fibroblasts 
 
To determine whether TNF-α interferes with circadian gene expression, we used NIH 
3T3 fibroblast cultures synchronized by a 2-h serum shock; this system elicits a well 
described circadian expression of central clock genes and CCGs for at least three 
cycles (19). We analyzed serum shocked fibroblasts challenged over time with or 
without TNF-α (10 ng/ml). RNA was extracted every 4 h thereafter up to Zeitgeber 
time (ZT) 36 and analyzed by using quantitative real-time RT-PCR methods. Within 
the first 12 h, the course of the examined clock gene expression was not altered by 
TNF-α treatment. However, around the peak (ZT 20-28), TNF-α strikingly suppressed 
the expression of the central clock genes Per1, Per2, and Per3 and of the CCGs Dbp, 
Tef, and Hlf. Peak expression of Rev-erbα mRNA at ZT 20 was slightly increased, 
whereas Bmal1 expression was not affected by TNF-α. Clock expression was slightly 
increased. For all genes, TNF-α did not affect the phases but rather attenuated the 
amplitude of expression (Fig. 1A). Therefore, we assessed the extent of clock gene 
expression at their main peak at ZT 24. TNF-α induced a significant reduction of 
gene expression for Per1, Per2, Per3, Dbp, Tef, and Hlf genes. Rev-Erbα expression, 
as assessed at its peak of expression at ZT 20, remained unchanged by TNF-α, as 
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did Clock (Fig. 1B). We extended the time of observation over a second circadian 
cycle and analyzed rhythmic expression up to 60 h. In this, emphasis was placed on 
Dbp expression, because its amplitude was the most affected by TNF-α. Rhythmicity 
and period length of Dbp expression were not changed by TNF-α, but its amplitude 
was severely suppressed at both peaks (Fig. 1C). To determine whether the TNF-α-
mediated suppression is reversible, we washed out TNF-α after the first cycle (at ZT 
24) and analyzed the second peak at ZT 48. By washing out TNF-α, the second peak 
of expression of Per1 and Per2 was restored, and Dbp expression increased 
compared with the control where TNF-α still led to reduced peak expression. The 
expression of Clock was not affected when extending the time of TNF-α treatment to 
48 h (Fig. 1D). Moreover, the suppression of Dbp, Per1, and Per2 gene expression in 
synchronized NIH 3T3 fibroblasts is clearly dose-dependent, being most significantly 
affected by concentrations > 1 ng/ml TNF-α. The expression of Clock remained 
unchanged irrespective of the dose of TNF-α (Fig. 1E). 
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Fig. 1. TNF-α impairs expression of clock genes in synchronized NIH 3T3 fibroblasts. (A) 
TNF-α attenuates circadian Per1/2/3 and PAR bZIP family (Dbp, Tef, and Hlf) gene expression. After 
serum shock (ZT 0-2), cells were kept in serum-free medium with TNF-α (10 ng/ml; open circles) or 
without the cytokine (filled circles) and analyzed every 4 h with quantitative real-time RT-PCR. Results 
are shown as x-fold variations to nonsynchronized fibroblast cultures at ZT 0; three independent 
experiments; mean values ± SD. (B) Per and PAR bZIP family genes are significantly down-regulated 
at the 24-h peak (TNF-α: gray bars; controls: black bars), whereas Clock and Rev-Erbα are not 
affected. Expression of Rev-Erbα was assessed at its peak at ZT 20. Data show one representative 
experiment done in triplicate (mean ± SD) of four experiments. (C) The amplitude of Dbp expression 
in serum-shocked NIH 3T3 fibroblasts was attenuated during 60 h in the presence of TNF-α (open 
circles) compared with controls (filled circles). (D) Withdrawal of TNF-α after the first peak at ZT 24 
shows that the suppression of Dbp, Per1, and Per2 at the second peak at ZT 48 is reversible. After 
serum shock, cells were treated with TNF-α for 24 h (gray bars), or for 48 h with or without a 
withdrawal of TNF-α after 24 h (white and black bars, respectively). Gene expression was compared 
to mock-treated cells at the respective ZT (100% expression). Data show one representative 
experiment done in triplicates (mean ± SD) of three experiments. (E) The suppression of the 
expression of Dbp, Per1, and Per2 in synchronized fibroblasts at ZT 24 is dose-dependent being 
significant (P< 0.005) at doses higher than 1 ng/ml TNF-α. Data show the mean ± SD of three 
independent experiments performed in triplicates. For BDE, we used the independent-sample t-test ; 
*, P ≤ 0,05; **, P ≤ 0,005; ***, P ≤ 0,0005. 
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IL‐1β but neither IFN nor IL‐6, shares with TNF‐α the effect to down‐regulate 
clock genes 
 
Besides TNF-α other cytokines are produced by TLR-activated macrophages and 
dendritic cells that have been implicated in the sickness behavior syndrome, namely 
the proinflammatory cytokines IL-1, IL-6, and IFN-γ and type I IFN cytokines IFN-α 
and -β (20). Therefore, we examined whether the effect of TNF-α is clock genes is a 
unique property of TNF-α or is shared by other cytokines. Besides TNF-α also IL-1β 
suppressed the expression of both, Dbp and Per3 (Fig. 2). The expression of Dbp, 
Per1, Per2, and Per3 was not inhibited by treatment of synchronized fibroblasts with 
IL-6 and IFN-α. IFN-γ induced a significant, albeit minor, suppression of Dbp 
expression. 
Fig. 2. Cytokine effects on Dbp, Per1, Per2, and Per3 in NIH 3T3 fibroblasts. Confluent cells 
were synchronized with 50% horse serum for 2 h (ZT 0-2). After serum shock, cells were kept in 
serum-free medium with TNF-α (10 ng/ml), IL-1β (10 ng/ml), IL-6 (10 ng/ml), IFN-α (10 ng/ml), IFN-
γ (20 ng/ml) or without cytokines and analyzed at ZT 24 with quantitative real-time RT-PCR. Results 
are shown as percent of expression to noncytokine-treated fibroblast cultures; one representative 
experiment of three; mean values of triplicates ± SD; independent sample t-test; *, P ≤ 0,05; **, P ≤ 
0,005; ***, P ≤ 0,0005. 
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TNF‐α interferes with E‐box‐dependent transcription of clock genes 
 
Circadian transcriptional activation of Per genes and of the PAR bZip transcription 
factor genes Dbp, Tef, and Hlf is thought to depend on the binding of the 
heterodimer BMAL1:CLOCK to the canonical or non-canonical E-box, a basic helix-
loop-helix transcription factor-binding site ideally harboring the sequence CACGTG 
(21). In our study, TNF-α affected suppression only of the transcription of those 
clock genes harboring an E-box upstream of the transcription initiation site (Per 
genes and Dbp, Tef, and Hlf). No suppression was observed on Bmal1 and Clock 
expression, their transcription not being E-box-dependent. Thus, TNF-α may 
interfere with E-box-mediated transcriptional activation. To test this hypothesis, we 
performed transient transfections of NIH 3T3 cells with luciferase reporter genes 
under the control of the native 3- or 1.7-kB promoter sequences of mouse Per1 and 
Per3, respectively, and of the 1-kB promoter of Bmal1 (Fig. 3A). Consistent with the 
gene expression studies, Per1 and Per3 promoter activity was suppressed after TNF-
α administration but not that of the Bmal1 promoter, which is devoid of E-box 
elements (Fig. 3B). To specify the possible effect on E-boxes, we performed assays 
using NIH 3T3 cells stably transfected with a luciferase reporter plasmid consisting of 
three E-boxes within 2.0 kb of the 5’ flanking region of the mouse Per1 gene with 
their immediate flanking sequence linked together and joined to the thymidine kinase 
promoter (22) (Fig. 3A). Again, treatment with TNF-α reduced luciferase activity by 
45%, corresponding to the basal activity of the basic pGL3-TK vector without E-
boxes (Fig. 3C). An E-box reporter construct of the Dbp gene (Dbp-E-box857; Fig. 
3A) that was cotransfected with plasmids expressing CLOCK and BMAL1 proteins 
showed expression reduced by 67%, indicating that overexpressed CLOCK and 
BMAL1 are still efficiently blocked. In contrast, with the mutated E-box (ACCAGT 
instead of CACATG) reporter construct (Dbp-857 mut), the activity was significantly 
derepressed (Fig. 3D). We suggest therefore that TNF-α suppresses E-box-mediated 
transcription of clock genes. Thus, selective down-regulation of clock genes or CCGs 
is likely to depend on the presence of E-box elements in the respective genes. 
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Fig. 3. TNF-α suppresses E-box-mediated transcription of clock genes. (A) Schematic 
representation of the luciferase reporter genes used. mPer1-luc (3-kb promoter fragment) and mPer3-
luc (1.7 kb promoter fragment) contain promoter sequences upstream of their genes in the pGL3basic 
vector. pBmal1-luc is regulated by a 1-kb promoter fragment and a 1-kb sequence of the 3‘UTR from 
mBmal1 gene. E54-TK consists of the three E-boxes of the mouse Per1 gene and their immediate 
flanking sequences in front of a TK promoter. DBP-Ebox857-luc contains one of four E-boxes of the 
Dbp promoter regulating the activity of a SV40 promoter. (B) Native clock gene promoters bearing an 
E-box are affected by TNF-α. Percent luciferase expression of mPer1-luc, mPer3-luc, pBmal1-luc 
transfected NIH 3T3 cells after treatment with 10 ng/ml TNF-α overnight compared to untreated 
controls (100% luciferase expression) is shown. (C) E-boxes of mPer1 are affected by TNF-α 
treatment. TNF-α significantly reduces E54-TK-dependent luciferase expression but not pGL3-TK 
lacking E-boxes and flanking sequences as shown by raw data (RLU, Relative Light Units; Left) and 
percent inhibition (Right). (D) The E-box of Dbp gene at position +857 is repressed by TNF-α even 
when CLOCK and BMAL1 are overexpressed. Cotransfection with CLOCK and BMAL1 leads to four to 
five times higher relative luciferase activity of 857wt compared with the mutated E-box vector 
(857mut) indicating that the interaction of CLOCK:BMAL1 with the E-box is functional. Luciferase 
activity is efficiently suppressed by overnight treatment with TNF-α as shown by raw datas (Left) and 
percent inhibition (Right). TNF-α leads to a higher repression in 857wt than in 857mut. For all assays, 
mean ± SD of triplicates from one representative experiment of three; independent sample t-test. 
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Reduction of clock genes and CCGs in TNF‐α‐treated mice 
 
To assess the effect of TNF-α on the expression of clock genes in vivo, C57Bl/6 mice 
were constantly infused with TNF-α (1,5 μg/day or 0,075 mg/kg per day) via an 
osmotic minipump inserted s.c. on the back of the mice over a period of 7 days (see 
Materials and Methods). The dose chosen is ≈10-fold lower than the dose used to 
induce a septic shock-like disease in rats (0,7 mg/kg, administered intravenously) 
(23). Histopathology revealed no evidence for TNF-α-induced vascular damage, 
hemorrhages, or inflammation in the liver, lung, and kidney based on morphological 
criteria and on the expression of heme oxygenase (HO-1), a marker for oxidative 
stress. Macrophages of mice infused with TNF-α showed signs of being activated in 
the liver and kidney (supporting information (SI) Fig. 6). We found TNF-α serum 
concentrations at 43 (±10.9) pg/ml at day three in TNF-α-treated mice compared 
with 10 (±0.8) pg/ml in controls (SI Fig. 7). In mice with experimental septic shock 
the respective value for TNF-α exceeds 10 ng/ml (24). In controls, osmotic pumps 
were filled with diluent (PBS, 0.1% BSA). Total RNA was extracted from the liver of 
mice treated with TNF-α or control; expression of clock genes was tested at day 
three at ZT 11.5 and ZT 15.5 (ZT 0 = 6 a.m. lights on, ZT 12 = 6 p.m. lights off), 
when we encountered maximal inhibition of locomotion (Fig. 5A). As shown for 
fibroblasts in vitro, TNF-α also suppressed the expression of Dbp, Tef, and Hlf, and 
Per3, but not of Bmal1 and Clock (Fig. 4). Although Per1 and Per2 were down-
regulated, this was not significant. However, at a later time point (ZT 15.5), when 
Per2 normally reaches its peak of expression, significant suppression of Per2 was 
observed (Fig. 4 Lower). In contrast to the fibroblast data, we found that TNF-α 
suppressed the expression of Rev-Erbα. TNF-α induced reduction of expression of 
the Per genes and of PAR bZip transcription factor genes is likely to influence the 
expression of clock output genes. Among the genes that are positively regulated by 
DBP is the liver-specific albumin gene (25). The capacity of TNF-α to interfere with 
Dbp mRNA expression is congruent with the observation of a decrease in albumin 
serum concentration by 41% in TNF-α-treated mice compared with controls (SI Fig. 
8). TNF-α has already been described as inhibiting albumin synthesis in liver cells, 
but the mechanisms remain elusive (26). Taken collectively, these data provide 
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evidence that the suppressive role of TNF-α on Dbp is associated with impaired 
activation of its target gene. TNF-α-treated mice also show higher endogenous 
expressions of IL-1β and TNF-α in the liver (both genes are well known to be 
induced by TNF-α (28)); the level of expression of these cytokines correlates with 
each other (SI Fig. 9). Furthermore, the increased expression of the cytokines in the 
liver is associated with a decrease of the CCG Dbp, Hlf, and Tef; the extent of the 
decrease of these PAR bZip transcription factors fits to the TNF-α expression in 
individual mice (SI Fig. 9). 
 
Fig. 4: Impaired expression of clock genes in livers of TNF-α infused mice. Animals were 
entrained to a LD cycle during 2 weeks, and their locomotor activity was constantly monitored via a 
passive infrared sensor and a running-wheel. Mice were then implanted with osmotic minipumps 
delivering TNF-α (light gray bars) or saline as control (dark gray bars). On the third day after the 
operation, mice were killed at ZT = 11.5 or = 15.5 (ZT = 0, light on; ZT = 12, light off). Livers were 
extracted and gene expression assessed by real-time PCR. (A) Per1/2/3, Rev-Erbα and PAR bZip 
family genes, Dbp, Hlf, and Tef, are down-regulated at both time points, the suppression of PAR bZip 
family genes is highly significant. In contrast to fibroblast data, Rev-Erbα is strongly down-regulated. 
Results are shown as percentages relative to the mean of the control group. One representative 
experiment of three is shown (n = 6 per group; Mann-Whitney test. *, P ≤ 0,05; **, P ≤ 0,005). 
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TNF‐α reduces Dbp expression in the SCN in the hypothalamic region. 
 
To verify whether the effect of TNF-α is sustained across the blood-brain barrier and 
reaches the SCN, the expression of Dbp was quantified. As described above, mice 
were implanted with minipumps releasing TNF-α or diluent; mice were killed after 3 
days at ZT 6, when peak expression of Dbp was expected. A slight (-15%), but 
statistically significant reduction of Dbp expression (P = 0.003) can be seen by in situ 
hybridization in the SCN of TNF-α-treated mice (SI Fig. 10). To verify the time point 
of the rhythm, we used Bmal1, which, at peak expression of Dbp, is not detectable. 
Indeed, unlike Dbp mRNA-positive cells, Bmal1 transcripts were not identified by in 
situ hybridization at ZT 6. 
 
TNF‐α reduces locomotor activity and promotes increased rest time in mice 
 
The function of TNF-α to interfere with the transcription of distinct clock genes or 
CCGs prompted us to evaluate whether TNF-α alters the circadian rhythm and/or the 
amount of locomotor activity in vivo. The timing and extent of locomotor activity 
were assessed with infrared sensors as well as by monitoring running-wheel activity 
in mice recorded under a 12-h light/12-h dark (LD) schedule. The surgical procedure 
led to a decrease in locomotor activity that lasted for 48 h (infrared; Fig. 5A Upper). 
However, beside the more pronounced impairment of locomotor activity on days 1 
and 2, TNF-α led also to a severe suppression of locomotor activity on day 3; on this 
day, control mice had attained baseline levels of activity. When running-wheel 
activity was assessed, an analogous picture emerged with maximum inhibition at day 
3 (Fig. 5 A Lower and B). At later time points, especially on days 5 and 6, TNF-α no 
longer exerted any effect on locomotor activity. This is most likely due to a failed 
release of TNF-α from the pump, because starting at day 4, hemorrhagic necrosis 
developed at the site of the pump. This local side effect was noticed when pumps 
were filled with TNF-α but not with control solution and has been described in areas 
of s.c. injection of TNF-α in mice (3 μg for 5 days) (29). Our results show that TNF-α 
leads to a decrease in the total amount of locomotor activity as measured by a 
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running-wheel and infrared sensors until day 4 (Fig. 5A). The activity in both groups 
was still restricted to the dark period, and highest loss of activity in TNF-α treated 
animals can be observed during the second half of the active period (Fig. 5B). 
Further, based on these observations, we chose day 3 to investigate the frequency 
and duration of rest episodes during the LD period (SI Fig. 11A). During the light 
period, no change was observed. But in the dark period, when mice are usually 
active, a significant increase in rest episodes lasting 6-60 min was detected. As 
readout of the endogenous circadian clock, we assessed locomotor activity in 
constant darkness (“free-running condition”) after implantation of the minipumps and 
calculated the period length (τ). We observed no changes in the periodicity of τ (SI 
Fig. 11B). Taken together, mice treated continuously with TNF-α show reduced 
motor activity and more consolidated rest time but no change in period length under 
free-running conditions. These findings are consistent with experiments with 
fibroblasts showing that the amplitude of the expression of clock genes and CCGs are 
attenuated by TNF-α, rather than their circadian rhythm itself. 
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Fig. 5: TNF-α reduces locomotor activity of mice but does not alter their circadian rest-
activity cycles. (A) Reduced locomotor activities in mice with constant TNF-α infusions are detected 
from day 1-4. Boxplot showing the changes of locomotor activity for each day after minipump 
implantation (TNF-α, 1.5 μg/day, for 6 days) or saline as control, compared with the baseline (mean 
of 3 days immediately before the operation). The TNF-α-treated group is shown as light gray bars and 
the control group as dark gray bars; circles are outliers, and triangles are extreme values. Six mice per 
group were analyzed. Data show one experiment (ANOVA for repeated measures, followed by 
independent-sample t-tests; *, P ≤ 0,05). The effect of TNF-α to impair locomotor activity was 
confirmed at day 3 in two independent experiments. (B) TNF-α reduces locomotor activity in the 
second half of the dark phase. Actograms (as measured by infrared and running-wheel) show data 
from six individual mice before and after the minipump insertion. Each line represents one individual 
mouse per treatment, 1 day before the implantation of minipumps (baseline, BL) and 3 days after the 
operation (OP). 
 
 
Discussion 
Whereas the molecular mechanisms provided by clock genes to maintain the 
circadian rhythm are becoming increasingly clear, the potential influences of the 
immune system on the molecular clockwork remain to be explored. Here, we provide 
evidence that TNF-α interferes with the expression of clock genes, namely the Per 
genes and the PAR bZip genes Dbp, Tef, and Hlf. TNF-α suppresses the expression 
of these genes in fibroblasts (and attenuates their amplitudes) in vitro and in vivo in 
the liver of mice infused with this cytokine. That the same genes (with the exception 
of Rev-Erbα) are prone to TNF-α stimulation in vitro compared with in vivo speaks 
for a rather direct effect of TNF-α, although we cannot exclude other intermediates 
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involved leading to the same response. In situ hybridization shows that the s.c. 
administration of TNF-α also leads to reduction of Dbp expression in the central 
circadian pacemaker, the SCN. Thus, it is tempting to speculate that TNF-α is likely 
to reach the SCN via the blood and to bind to TNF receptor (TNF-R) on neurons. At 
least in the hippocampus, both TNF-RI and -RII, are expressed (30). In the present 
study E-box regulatory elements of clock genes are found to play a pivotal role in the 
effect of TNF-α to inhibit clock gene expression. First, only clock genes with E-boxes 
in their promoter, the PAR bZip genes Dbp, Tef, and Hlf and the Per genes, are 
affected by TNF-α, whereas clock genes devoid of E-boxes such as Clock and Bmal1 
are not affected by TNF-α. Second, mutated E-boxes provide protection of TNF-α-
induced suppression of clock reporter genes. E-boxes are functionally important 
components of DNA promoters that guide the expression of clock genes and thereby 
influence the circadian rhythm, including the sleep-wake cycle. Rhythmic binding of 
CLOCK and BMAL1 depends on E-boxes and is a prerequisite for robust waves of 
gene expression characteristic of circadian transcription (31, 32).  
The effects of TNF-α on clock gene expression also become apparent when studying 
clock-dependent genes. Dbp has been described to mediate transcription of the 
albumin gene in hepatocytes (25). Albumin serum concentrations are found here to 
be lowered by 41% in TNF-α-treated mice compared with controls. 
Recording of locomotor activity of TNF-α-treated mice shows more rest episodes 
during spontaneous activity. In line with the finding that TNF-α does not alter 
circadian rhythm in cultured fibroblasts but rather lowers the extent of expression of 
distinct clock genes, TNF-α did not influence period length of the circadian rhythm 
under “free running” conditions. Of interest for the findings presented here are data 
showing that the deletion of the Dbp gene in mice results in only a slight reduction of 
period length but in a striking impairment of spontaneous locomotor activity and 
running-wheel activity (33, 34). Whereas Tef and Hlf single-knockout mice show an 
increased period length, the inactivation of all three genes, Dbp, Tef, and Hlf, 
resulted in an unchanged circadian period length (27). Thus, a normal period length 
may be due to opposite effects leading to mutual neutralization of indirect clock gene 
dysfunction. Besides lowering the expression of PAR bZip transcription factors, TNF-α 
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impaired Per1, Per2, and Per3 mRNA. Target disruption of these genes results in 
slightly (Per3-/- mice) or more dramatically (Per1-/- mice) shortened period lengths or 
eventually gives rise to arrhythmic behavior (Per2-/- mice). Taken collectively, TNF-α 
interferes with the expression of E-box-dependent clock genes and leads to 
prolonged rest episodes during spontaneous activity of mice. 
Sleep architecture in humans is affected by the endogenous circadian pacemaker, 
which regulates the timing of the sleep-wake cycle, presumably by circadian 
expression of clock genes (13, 35). Enhanced NREM sleep has been shown in mice 
treated with muramyl dipeptides, which activate TLR2 and TLR4 on macrophages 
(36, 37). TNF-α, as well as IL-1, is produced by TLR2- and TLR4-activated 
macrophages and is well described to enhance NREM sleep (11, 38, 39). In light of 
the overlapping properties of TNF-α and IL-1 on NREM sleep, it is interesting that 
our studies show IL-1 to share with TNF-α the inhibitory effect on expression of the 
Dbp and Per3 genes in fibroblasts. As recently outlined, the effects of IL-6 on sleep 
differs from IL-1 and TNF-α, in that it may also act on systems involved in NREM 
sleep but not in REM sleep, which is suppressed by TNF-α and IL-1 but not by IL-6 
(40). In this context, it may be of relevance that the expression of Dbp is found here 
not to be affected by IL-6. Although the expression of Dbp and Per1 is also not 
inhibited by IFN-α, IFN-γ only slightly interfered with Dbp expression. This is 
remarkable, because in mice, the daily injection of IFN-α or -γ has been reported to 
lower Per1, Per2, Per3. and Clock after 6 days of treatment (41). The absence of 
effects of IFN-α and -γ on expression of the Per genes by synchronized fibroblasts in 
vitro indicates that IFNs down-regulate the Per and Clock genes by E-box-
independent mechanisms or induce production of other clock gene-regulating factors 
when mice are treated over a long time period with the cytokines. 
In infectious diseases, TNF-α serves to successfully eliminate the infectious agent. 
The function of TNF-α to interfere with the expression of clock genes, to impair 
locomotor activity, and to enhance rest may provide the link between the activation 
of the innate immunity and fatigue associated with infectious and autoimmune 
diseases, such as multiple sclerosis, RA, or Crohn’s disease. In these disorders, both 
fatigue and elevated TNF-α gene concentrations have been described (6, 42, 43). It 
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is still debated whether sleep changes in infections are beneficial to the host defense. 
Rabbits infected with E. coli, Staphylococcus aureus, or Candida albicans showed an 
improved prognosis when their sleep duration was prolonged (44). In this context, it 
is to be noted that Per2-/- mice are partially protected from LPS-induced shock (45). 
During the TNF-α induced “inflammatory clock gene response”, the expression of 
Per1, Per2, and Per3 genes and of the PAR bZip transcription factors Dbp, Tef, and 
Hlf is down-regulated, the locomotor activity reduced, and rest episodes prolonged. 
Although this pathway may induce an adaptive state in infectious diseases, the 
“inflammatory clock gene response” may, by inducing fatigue, diminish quality of life 
in autoimmune diseases. Our study will serve to lay an important foundation for 
further exploration of the connection between the TNF-α-induced “inflammatory 
clock gene response” and the TNF-α-triggered reduction of locomotor activity. 
 
Materials and Methods 
Cytokines 
Recombinant murine (rm) TNF-α, rm IL-1β, and rm IL-6 were purchased either from 
Sigma (St. Louis, MO) (in vitro time course assays) or from Peprotech (London, U.K.) 
(in vivo assays); rm IFN-α from Immunotools (Friesoythe, Germany), and rm IFN-γ 
from Roche (Rotkreuz, Switzerland). 
Synchronization of fibroblasts by serum shock 
NIH 3T3 fibroblasts were grown in DMEM (Gibco, Basel, Switzerland) supplemented 
with 10% FBS (PAA Laboratories, Pasching, Austria) and Glutamax (Gibco). For 
serum shock, cells were grown to confluency in 6-cm tissue culture dishes. At time t 
= 0, the medium was exchanged by 50% horse serum (Gibco) in DMEM/Glutamax; 
after 2 h, the medium was replaced with serum-free DMEM/Glutamax, with or 
without TNF-α. At the indicated time points, tissue culture dishes were washed once 
with Hanks solution, frozen on a layer of liquid nitrogen, and kept at –70°C until the 
extraction of whole-cell RNA. 
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Transfection and luciferase assays 
Unsynchronized NIH 3T3 cells were transfected with the following constructs by 
using Lipofectamine Plus (Life Technologies, Basel, Switzerland) or Trans-Fectin 
(BioRad, Hercules, CA) according to the manufacturer’s protocol: mPer1-luc (46), 
kindly provided by David Earnest (Texas A&M, College Station, TX); E54-TK (22), 
kindly provided by Sato Honma (Hokkaido University, Sapporo, Japan); Bmal1-luc 
(19), DBP-Ebox-luc and mut Ebox, pCDNA3.1-Clock and pCDNA3.1-Bmal1 (47), 
kindly provided by U. Schibler (University of Geneva, Geneva, Switzerland); mPer3-
luc (48), kindly provided by P. Sassone-Corsi (IGBMC, Illkirch, France). As an internal 
control for transfection efficiency, a GFP construct (pMax-GFP; Amaxa, Cologne, 
Germany) was cotransfected 1:10. 
Twenty-four hours after transfection, the medium was replaced with serum-free 
DMEM/glutamax with or without TNF-α (10 ng/ml). After ≈15 h cells were lysed by 
using Passive Lysis Buffer (Promega, Wallisellen, Switzerland) and enzyme activity 
was measured by the Luciferase Assay System (Promega). Bioluminescence was 
measured with a Luminometer (Berthold Technologies, Regensdorf, Switzerland) and 
normalized to transfection efficiency or protein concentration. 
Animal groups and locomotor activity recording 
Seven-week-old C57Bl/6 male mice (Harlan Breeding Laboratories, AD Horst, The 
Netherlands) were housed in individual cages, equipped with a running-wheel and a 
passive infrared sensor in a temperature-controlled sound-proof light-tight room. 
Food and water were available ad libitum. We allowed mice 10-15 days of 
acclimatization to a LD cycle (light on at 0600, i.e., ZT 0; light off at 1800, i.e., ZT 
12). Mice were operated under deep isoflurane anaesthesia, and 30 μg Temgesic 
anesthetic (buprenorphine; Essex Chemie, Lucerne, Switzerland) was applied. TNF-α 
(1.5 μg/day, diluted in 0.1% BSA/PBS) or 0.1%BSA/PBS as a control was 
administered s.c. by using osmotic minipumps (Model 1007D; Alzet, Cupertino, CA) 
implanted on the back, for 6 days. Locomotor activity was continuously measured via 
running-wheel and infrared sensors based on 1-min episodes by using the 
Chronobiology Kit software (Stanford Software Systems, Santa Cruz, CA) as 
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described (49, 50). Rest episodes were defined as 1-min units with activity = zero. 
The free-running period of locomotion was calculated by periodogram analysis for 
days 2-6 after minipump implantation, when the mice were kept in constant 
darkness. In gene expression studies, livers were extracted 3 days after minipump 
insertion at two different ZTs known to approximately represent the peak of 
expression of Dbp (ZT = 11.5) or Per2 (ZT = 15.5). Livers were frozen in TRIzol 
(Invitrogen, Basel, Switzerland) for subsequent RNA extraction. All experimental 
procedures were approved by the local committee of the veterinary office and in 
strict accordance with Swiss regulations on animal welfare. 
RNA isolation and gene expression analysis 
The method for RNA extraction, RT-PCR, and quantification of gene expression is 
described in the SI Text. 
In situ hybridization 
The method for in situ hybridization was published (51) and is described in the SI 
Text. 
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Suporting information 
SI Figures 
 
SI Fig. 6. Photomicrographs of histological sections of liver, lung and kidney with (top row) and 
without (bottom row) TNF-α treatment: The liver shows an increase in HO-1 positive Kupffer cells. At 
high power magnification the cells appear also larger. No morphologically apparent liver cell damage 
is however detected. The lung shows unremarkable numbers of HO-1 positive macrophages in the 
bronchial mucus layer. No increase in HO-1 positive alveolar macrophages is seen. At high power 
magnification (hematoxillin eosin staining) increased numbers of megakaryocytes (indicated by 
arrows) are seen trapped within the alveolar vascular bed. There is, however, no evidence of 
pulmonary edema or acute pulmonary damage. Sections of the kidney (hematoxillin eosin staining) 
are unremarkable. The scale bar represents from left to right 400 μm, 50 μm, 200 μm, 50 μm and 
100μm, respectively. 
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SI Fig. 7. At day 3 (ZT 15.5) after minipump insertion, serum was collected and TNF-α was 
measured by ELISA. Data are given as the mean ± SD of TNF-α serum concentrations measured in 
six animals per group. Independent samples t-test, P = 0.001. 
 
 
SI Fig. 8. Decreased concentrations of albumin in serum of TNF-α-treated mice. Serum was collected 
at day three after minipump implantation at ZT 15.5 and albumin concentrations were measured as 
described in materials and methods. Data show the mean ± SD of serum albumin concentrations in 
mice (six mice per group). 
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SI Fig. 9. IL-1β expression correlates to TNF-α expression, both being increased in TNF-α-treated 
animals (circles with different colors, each individual mouse representing one color) compared to 
animals infused with PBS (blue open circles) (day 3, at ZT 15.5; 6 mice per group). In contrary, Dbp, 
Hlf, and Tef are negatively correlated to the relative TNF-α expression. 
 
SI Fig. 10. TNF-α impairs expression of the clock output gene Dbp in the SCN. (A and B) Dbp and 
Bmal1 expression in the SCN at ZT 6 as determined by radioactive in situ hybridization. At the time 
point of peak expression of Dbp, when Bmal1 expression is lowest, TNF-α leads to a significant 
reduction by 15% of the Dbp mRNA. (means ± SEM of six consecutive sections per mouse SCN; four 
mice; paired t-test; * P=0.003). 
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SI Fig. 11. (A) Mice treated with TNF-α show increased long rest epochs in the dark phase. Analysis 
of rest epochs was performed at day 3 of TNF-α and control infused mice; the analysis being 
performed separately for the light and dark period. The data show the differences in numbers of 1-
min episodes with activity = 0 compared to baseline (mean of the three days before minipump 
insertion). The occurrence of rest was arbitrarily subdivided in episodes for durations with rest = 0 
activity counts: up to 1 min rest, between 2 and 5 min, 6 and 60 min, and more than 60 min. (ANOVA 
for repeated measures, followed by independent-samples t-test; * P ≤ 0,05). (B) TNF-α does not 
affect the period length measured in constant darkness. On day 1 after minipump insertion the lights 
were turned off and the mice were kept in constant darkness. The circadian period of locomotion and 
running-wheel activity was determined by periodogram analysis over the 5 days in constant darkness. 
Independent-sample t-tests were performed. TNF-α (1.5 μg/day; light gray bars) or saline as control 
(dark gray bars). 
 
SI Table 1. Sequences for primers and probes, normal concentrations used were 250 nM for Probes 
and 400nM for the primers. 
  53
SI Text 
RNA isolation and gene expression analysis 
Whole-cell RNA from cultured cells was extracted using the NucleoSpin-RNA II kit 
(Macherey-Nagel, Switzerland). RNA from mouse tissues was extracted by 
homogenization of the organ in TRIzol (Invitrogen) according to the manufacturer’s 
instructions. Subsequently, RNA was reverse-transcribed using random hexamers 
(Promega, for the in vitro assays; Roche, for the in vivo assays) and AMV reverse 
transcriptase (Promega, for the in vitro assays) or M-MuLV reverse transcriptase 
(Roche, for the in vivo assays). The cDNA equivalent to 50 ng of total RNA was PCR-
amplified in an ABI PRISM 7700 detection system (PE-Applied Biosystems) using the 
TaqMan Universal PCR Master Mix (Applied Biosystems) and quantified as follows. 
Primers and probes for Taqman analysis were either purchased from Applied 
Biosystems or purchased from Microsynth, Balgach Switzerland as described in detail 
in SI table 1. The relative levels of each RNA were calculated by the 2-ΔΔCT method 
(CT standing for the cycle number at which the signal reaches the threshold of 
detection); 18s rRNA was used as a housekeeping gene. Each CT value used for 
these calculations is the mean of two duplicates of the same reaction. Relative RNA 
levels are expressed as x-fold variations compared to ZT = 0 (time course 
experiments) or as percentages of the average control groups (in the in vitro one-
time-point experiments and in the in vivo experiments). 
 
In situ hybridization 
 
After infusion of mice with saline or TNF-α mice were killed at day three at ZT 6. 
Brains were embedded in paraffin and sectioned at 7-µm-thickness and hybridized 
with 35S-rUTP labeled riboprobes as described (51). The Bmal1 probe corresponded 
to nucleotides 654-1290 (accession no. AF015953) and the Dbp probe to nucleotides 
2-951 (accession no. NM016974). Quantification was performed by densitometric 
analysis of autoradiograph films using the Molecular analyst program (Bio-Rad). Data 
from the SCN were normalized to the lateral hypothalamus next to the SCN. For each 
treatment three animals were used and six sections per SCN were analyzed. We 
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assessed the relative mRNA abundance values by defining the highest value of each 
experiment in mock treated animals as 100%. 
Elisa 
The concentration of albumin and TNF-α in the serum of mice implanted with 
osmotic minipumps was determined by ELISA (Mouse Albumin ELISA Quantitation 
Kit, Bethyl Laboratories, TX and mouse TNF-α ELISA kit, KMC3012, Biosource). 
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4.2. CLOCK GENE MODULATION BY TNF‐α DEPENDS ON CALCIUM 
AND P38 MAP KINASE SIGNALING 
Petrzilka S., Taraborrelli C., Cavadini G., Fontana A. and Birchler T. 
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Abstract 
Treatment of fibroblasts for 24 hours with tumor necrosis factor-alpha 
(TNF-α) suppresses transcription of E-box driven clock genes (Dbp, Tef, Hlf 
and Per1, Per2, Per3) by yet unknown molecular mechanisms. The 
attenuation of clock genes has been suggested as a putative cause for the 
development of sickness behavior syndrome in infections and autoimmune 
diseases. Here, we studied the effect of TNF-α at early time points (<3 h) 
on intracellular signaling events and clock gene expression in fibroblasts. 
Interaction of TNF-α with TNFR1 (Tnfrsf1a, CD120a, p55) leads to 
downregulation of gene expression of D-site albumin binding protein 
(Dbp) and upregulation of negative regulators of the molecular clock, 
Period-1 and -2 (Per1 and -2), Cryptochrome-1 (Cry1), and Differentiated 
embryo chondrocytes-1 (Dec1). Since the decrease of Dbp is also observed 
in knockout cells for Per1/2 and Dec1, these genes are unlikely to be 
responsible for inhibition of Dbp. The effect of TNF-α on the clock genes, 
Dbp and Per1, in the early phase is dependent on p38 mitogen activated 
protein kinase (MAPK) and/or calcium signaling but not on the activation 
of NF-κB or AP-1. Taken collectively the data show p38 MAPK and calcium 
dependent, TNFR1 mediated transient increase of negative regulators of 
the molecular clock and an independent decrease of Dbp. 
 
 
 
Introduction 
TNF-α is a pleiotropic cytokine, which regulates the activation and function of a 
variety of cells including lymphocytes, fibroblasts and neurons (1). Its receptors, 
especially TNFR1, are ubiquitously expressed (2). In response to infections or in 
inflammation during autoimmune diseases (e.g. rheumatoid arthritis, multiple 
sclerosis, and inflammatory bowel disease) TNF-α is produced mainly by dendritic 
cells and macrophages (1). While infusions of TNF-α in cancer patients lead to 
severe daytime fatigue (3), treatment of patients with rheumatoid arthritis or 
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obstructive sleep apnoe syndrome with TNF-α blockers reduces disease-associated 
fatigue (4, 5). On the other hand, a disruption of the circadian clock can lead to the 
same symptoms. These data indicate a possible influence of TNF-α on the circadian 
system and thereby on fatigue. 
Recently, the effect of TNF-α on the molecular clock was investigated by our group. 
The data showed that TNF-α reduces the expression of E-box driven clock genes in 
cultured fibroblasts. Moreover TNF-α impairs nocturnal locomotor activity in mice, 
the effect being associated with a decrease of clock genes in the liver (6). These 
results suggest that TNF-α, by interfering with clock gene expression, might 
attenuate the circadian output of physiological and behavioural rhythms. Here, we 
aimed to elucidate signaling events leading to reduced clock gene expression, in 
TNF-α treated fibroblasts. 
The molecular clock is the cellular basis of circadian rhythms found in almost every 
organism ranging from bacteria, plants, and flies to humans. Circadian rhythms 
control many aspects of physiology and metabolism that allow organisms to 
anticipate regular changes in the environment (for reviews see (7)). In mammals, 
the integration of the day and night variation is provided by the suprachiasmatic 
nucleus (SCN) of the hypothalamus, which receives light information from the retina 
and synchronizes the clock of other brain areas and peripheral organs. Rhythms in 
single cells are thought to origin from interlocked transcription-translation feedback 
loops composed of positive transcriptional activators Clock and Bmal1 and negative 
elements such as Per and Cry. CLOCK and BMAL1 heterodimerize and bind to E-box 
enhancer sequences to promote transcription of Per1, Per2, Cry1, and Cry2, the 
products of which inhibit the activity of CLOCK:BMAL1 and hence their own 
transcription. A second feedback loop controls the expression of the positive clock 
element: REV-ERBα - itself activated through E-boxes by CLOCK:BMAL1 - 
rhythmically inhibits Bmal1 transcription (8). Post-translational modifications, such as 
phosphorylations, acetylations, sumoylations, among others allow for the fine tuning 
of the system generating a period of about 24 hours. Clock-controlled genes (CCGs) 
such as Per3 and the members of the PAR-bZip family of transcription factors, Dbp, 
Tef, and Hlf, also bear E-box motifs and their periodical expression contributes to the 
transformation of time information into physiological and behavioural rhythms. 
However, they are not integral part of the timing system. 
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TNF-α signals via two receptors: TNFR1 (p55TNFR, CD120a, TNFRSF1a) and TNFR2 
(p75TNFR, CD120b, TNFRSF1b). Whereas TNFR1 is ubiquitously expressed and more 
effective in sensing soluble TNF-α; TNFR2 has a higher affinity to the membrane 
bound cytokine, is involved in ligand passing to TNFR1 and bears its main functions 
in chronic inflammatory conditions. After receptor activation different intracellular 
adaptor proteins direct a complex array of signaling processes mediated by kinases, 
phosphatases, reactive oxygen intermediates, lipases, caspases, and 
sphingomyelinases. This leads to regulation of the cell function by transcription 
factors, G-protein signaling, and calcium ion signaling. In the TNF-α dependent 
intracellular signaling cascade, activation of caspases and the transcription factors 
NF-κB and AP-1 are important steps and have been found to regulate apoptosis and 
expression of chemokines and cytokines.  
This study was aimed to characterize the relevant intermediates of TNF-α signaling 
leading to altered clock gene expression. In the early response of fibroblasts to TNF-
α, transcription of negative clock gene regulators, namely Per1/2, Cry and Dec1 is 
activated. However, this induction is unlikely to be involved in downregulation of the 
clock-controlled gene Dbp. Impaired expression of Dbp was not dependent on 
caspase signaling, NF-κB, or AP-1 activation, but rather on the calcium ion signaling. 
Although there is less binding of acetylated histone H3 to the Dbp E-box 857, active 
deacetylation is not involved in the inhibition of Dbp by TNF-α. 
 
 
 
Results 
Immediate  early  induction  of  negative  clock  elements  parallels  fast  Dbp 
downregulation. 
 
To elucidate the direct effects of TNF-α on clock gene expression, we followed the 
immediate early response in NIH 3T3 fibroblasts. Upon treatment with TNF-α, 
expression of the clock controlled gene Dbp started to decrease after 15 min and 
reached 20% of control after 2 h (Fig. 1A, top left). A more delayed downregulation 
was observed when analyzing the expression of Per3 (Fig. 1A bottom middle). In 
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contrast, Per1 - and to a lower extent also Per2 - showed a significant transient peak 
of expression at 1 h after stimulation (Fig. 1A and B), with subsequent 
downregulation at later time points. Whereas both Cry1 and Dec1 were successively 
upregulated, the effect of TNF-α on Cry2 and Dec2 was less pronounced and the 
expression of Clock was hardly affected (Fig. 1A). The Per1 gene is regulated by two 
alternative promoters (13) regulating two alternative first exons, i.e. 1A and 1B. 
There was no difference in the Per1 peak induction at 1 h at the different promoters 
indicating similar regulation of both promoters (Fig. 1C). Taken collectively the data 
show that the clock genes analyzed respond differently to TNF-α treatment in a time 
dependent manner. 
In further experiments we tested if TNF-α induces increased degradation of Dbp 
mRNA. When blocking RNA transcription with Actinomycin D, no enhanced 
degradation of the short-lived Dbp mRNA was observed (Fig. S1A). However, we still 
found downregulation of pre-mRNA transcription by analysis of nascent transcripts 
(Fig. S1B). Hence, the effect of TNF-α to downregulate Dbp mRNA is due to a block 
in transcription and to the short lifespan of the mRNA. 
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Fig. 1: Early expression time course of clock genes in TNF-α treated NIH 3T3 fibroblasts. 
(A) Cells were stimulated with 10 ng/ml TNF-α in serum-free medium and mRNA expression of clock 
genes was analyzed at the indicated time points. Shown is the mean ± SD from 1 experiment in 
triplicates out of 2. (B) Per1 and Per2 are significantly induced and Dbp significantly inhibited after 1 h 
stimulation with TNF-α. Shown is the mean + SD; n=10 for Per1 and Dbp, n=6 for Per2. (C) 
Induction of Per1 is mediated by promoter 1A and 1B. NIH 3T3 were stimulated with 10 ng/ml TNF-α 
for 1 h; n=3 in triplicates. Shown is the mean + SD. For B and C we used paired sample t-tests; *, p≤ 
0.05; **, p ≤ 0.005; ***, p ≤h 0.0005 
 
 
Cycloheximide partly de‐represses Dbp inhibition 
 
To assess the dependency of Dbp downregulation on de-novo induced proteins, we 
performed assays with cycloheximide (CHX), a compound inhibiting protein 
biosynthesis. Five hours before TNF-α treatment, CHX was added to the cell cultures 
to inhibit protein translation. Thereafter, TNF-α was added only for 2 h since a longer 
exposure was found to induce apoptosis. The inhibition of Dbp expression was 
reversed but could not be de-repressed completely (Fig. 2). These results show that 
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the downregulation of Dbp is partly dependent on de-novo protein synthesis e.g. of a 
short-lived protein, but cannot be fully explained by a newly produced putative 
inhibitor, a fact also supported by the fast kinetics of Dbp downregulation. 
 
 
 
 
Fig. 2: The inhibition of Dbp is partly dependent on de-novo protein synthesis. After a 5 h 
pretreatment with cycloheximide (100 µg/ml) NIH 3T3 fibroblasts were stimulated with TNF-α for 1 h. 
Expression of untreated samples corresponds to 1. Shown is the mean + SD; n=3 in triplicates; paired 
samples t-test; *, p ≤ 0.05; **, p ≤ 0.005. 
 
 
The  transient  induction of negative regulators by TNF‐α  is not  involved  in 
later Dbp repression 
 
Mammalian Per genes are necessary for proper circadian rhythm generation. The 
induction of Per1 which acts as a negative feedback regulator could be important for 
the long-lasting TNF-α mediated downregulation of clock genes. Increased Per gene 
expression could lead to increased PER levels with putatively enhanced stability and 
activity by posttranscriptional modifications. To evaluate this hypothesis, we analyzed 
mouse embryonic fibroblasts (MEFs) lacking Per1, Per2, or both of them (11); those 
were compared to MEFs from corresponding wt mice. The baseline expression of the 
clock genes, Dbp, Clock, and Bmal1 is strongly reduced in Per1 -/- and lower in Per2 
-/- MEFs. For unknown reasons the expression of Dbp in Per1/2 -/- was not different 
compared to wt MEFs (Fig. 3A, left panel). However, in regard to the TNF-α response 
it becomes clear that the ability of TNF-α to downregulate Dbp gene expression was 
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still present in all genotypes when compared to baseline levels (Fig. 3A, right panel). 
Only a moderate loss of effect of TNF-α was seen in Per1 -/- and Per2 -/- MEFs cells, 
which however was not seen in double mutant cells. A faint upregulation of Clock 
and Bmal1 was observed in all genotypes upon TNF-α challenge (Fig. 3A right 
panel). In conclusion, the mutations of Per genes had no major impact on the effects 
of TNF-α on the clock genes analyzed. 
We also analyzed whether the TNF-α induced increase of Dec1 
(Stra13/Sharp2/BHLHB2) is responsible for downgegulation of Dbp (Fig 1A). This 
possibility raised because of recent data on DEC1 to impair E-box mediated 
transcription (14). Our data show that TNF-α effectively repressed Dbp gene 
transcription also in the human keratinocyte cell line, HaCaT. However, this effect 
was not de-repressed in Dec1-deficent HaCaT cells which have a targeted 
inactivation of Dec1 on both alleles through homologous recombination (Fig. 3B) 
(15). Taken collectively, our data show that despite of being upregulated at early 
time points neither PER1 and PER2 nor DEC1 seem to act as Dbp repressor 
molecules in TNF-α treated cells. 
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Fig. 3: The transient induction of negative clock regulators by TNF-α is not responsible for 
the repression of Dbp. (A) Dbp expression is repressed in wt, Per1, Per2 or Per1/2 double mutant 
MEFs, whereas the expression of the central clock genes Clock and Bmal1 remains unchanged. Cells 
were stimulated with 10 ng/ml TNF-α for 6 h. Shown is the mean + SD; left panel shows 1 
representative experiment done in triplicates where the gene expression in wt untreated cells is set to 
1; right panel is the mean of 3 independent experiments done in triplicates, where 1 represents the 
relative expression in the corresponding not TNF-α treated MEFs. (B) Dbp inhibition is independent of 
the presence of DEC1. Human keratinocytes, HaCaT cells, lacking the Dec1 gene were treated with 10 
ng/ml TNF-α for 4 h. Shown is the relative expression compared to untreated cells. Bars represent 
mean + SD; n=3 in triplicates. For A and B we used paired samples t-test; *, p ≤ 0.05; **, p ≤ 0.005; 
***, p ≤ 0.0005. 
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Signaling  via  TNFR1  leads  to  the  Per1  peak  and  Dbp  downregulation 
independent of NF‐κB, AP‐1 or caspase activation 
 
To analyze the dependency of TNF receptors on the clock gene responses - i.e. Dbp 
downregulation and Per1 peak - we generated cells from TNFR1 -/-, TNFR2 -/-, and 
wt mice. Using RT-PCR, TNFR1 mRNA expression was found to be abolished in 
TNFR1 -/- but still present in TNFR2 -/- MEFs. TNFR2 mRNA expression is detected in 
both knockout genotypes, because the tnfr2 deletion is situated outside of the 
amplified sequence (Fig. 4A). However, cell surface receptor expression is completely 
abolished in the respective knockouts (Fig. 4B). After 1 h TNF-α stimulation, the Per1 
peak could be detected in wt MEFs similar, although to a lower extent than in NIH 
3T3 cells. A Per1 peak was also seen in TNFR2 -/-, but not anymore in the TNFR1 -/- 
MEFs (Fig. 4C, left panel). To assay the downregulation of clock-controlled genes we 
looked at a later time point (6h), where inhibition is complete for all genes usually 
affected (6). Dbp and Per3 were downregulated in wt and TNFR2 -/-, but not in the 
TNFR1 -/- MEFs, whereas Clock and Per1 were unaffected in all genotypes (Fig. 4C, 
right panel). However, it is to note that, for unknown reasons, Per1 was not 
downregulated in wt MEFs which is in contrast to the strong inhibition seen in NIH 
3T3 cells. Our data show that both the TNF-α induced Per1 peak at early time points 
and the inhibition of Dbp is mediated by TNFR1. 
The major signaling pathway induced by TNFR1 leads to the activation of NF-κB 
transcription factor by its deliberation from the complex with the inhibitor of κB (IκB) 
proteins and subsequent translocation to the nucleus. The NF-κB transcription factor 
is composed mainly of the dimerized partners p65 and p50, transcriptional activity 
being strictly dependent on p65. Targeted inactivation of the RelA (p65) subunit of 
NF-κB in mice showed embryonic lethality due to massive liver apoptosis (16). The 
lethal phenotype could be reversed by breeding the mice in TNF-α deficient animals 
(17). Here, we analyzed p65 -/- MEFs compared to wt control MEFs of the same 
genotype. As expected in western blot of p65, p65-/- clearly distinguish from wt 
MEFs (Fig. 5A, left panel). Further, we analyzed the capability of these cells to 
activate a 4x-κB site element luciferase reporter gene and IL-6 induction. The p65 -/- 
MEFs had lower luciferase baseline levels and were not able to induce NF-κB after 
short TNF-α treatment (data not shown). In addition, p65-/- MEFs lacked the ability 
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to respond to TNF-α by inducing IL-6 mRNA (Fig. 5A, right panel). Since TNF-α 
treatment in p65 -/- MEFs leads to apoptosis starting around 4 h we analyzed the 
effects at time points 1 h (Per1 peak) and 4 h (Dbp repression). In p65 -/- MEFs 
TNF-α still induced the Per1 peak and repressed Dbp expression (Fig. 5B). This 
observation is supported by lack of effect on Dbp inhibition when adding 
wedelolactone (data not shown). This compound inhibits NF-κB-mediated gene 
transcription by blocking the phosphorylation and degradation of IκB. 
In addition to NF-κB activation, we also used an inhibitor to the c-jun N-terminal 
kinase (JNK), which phosphorylates c-Jun. Together with c-Fos, c-Jun forms the 
transcription factor AP-1. Again, early effects on Per1 peak and Dbp repression at 1 h 
were unaffected by the inhibition (Fig. 5C). The same holds true for inhibition of 
caspases with a pan-caspase inhibitor (Fig. S2). 
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Fig. 4: TNFR1-dependent Per1 induction and Dbp repression. (A) RT-PCR of TNFR1 and 
TNFR2 in MEFs from wt (1), TNFR1 -/- (2), TNFR2 -/- (3), or peritoneal macrophages (4). (B) 
Confirmation of cell surface expression of TNF receptors by FACS. B16 murine melanoma cells, wt, 
TNFR1 -/-, TNFR2 -/- MEFs were used for FACS staining with isotype (grey), TNFR1 (red line), and 
TNFR2 (green line) antibodies. (C) Different genotype MEFs were treated with 10 ng/ml TNF-α in 
serum-free medium for 6 h (left panel) or 1 h (right panel). Shown is the mean + SD; n=3 (left panel) 
or n=4 (right panel) both in triplicates. Paired samples t-test; *, p ≤ 0.05; **, p ≤ 0.005. 
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Fig. 5: The c-jun N-terminal kinase and p65 are not involved in the early effects of TNF-α 
on clock genes. (A) p65 -/- MEFs do not express p65 and fail to induce IL-6 upon TNF-α stimulation. 
Left panel: wt or p65 -/- MEFs were lysed and subjected to Western blot analysis. b-tubulin was used 
as a loading control. Right panel: wt or p65 -/- MEFs were treated with 10 ng/ml TNF-α in serum-free 
medium for 4 h (Dbp panel) or 1 h (Per1 panel). Shown is the mean + SD; n=4 in triplicates. There is 
no significant differences between wt and p65 -/- MEFs. (C) A JNK inhibitor does not prevent the Per1 
peak nor the Dbp repression. NIH 3T3 fibroblasts were pretreated with 1µM inhibitor for 1 h and then 
stimulated with 10 ng/ml TNF-α for another hour. 1 represents the expression level in untreated cells. 
n=3 in triplicates. 
 
 
Per1 peak and Dbp  inhibition  induced by TNF‐α are dependent on calcium 
ion signaling and activation of p38 MAPK 
 
Next we assessed the role of intracellular Ca2+ in the TNF-α induced clock gene 
response. As previously reported, we confirmed that calcium ionophores (ionomycin 
and PMA) induce Per1, but in addition we could also observe a downregulation of 
Dbp at the early phase (data not shown). To further confirm an involvement of 
intracellular Ca2+ signaling in the regulation mechanism, we used the intracellular 
calcium chelator BAPTA-AM. The addition of BAPTA-AM effectively reduced the Per1 
peak after 1 h treatment of NIH 3T3 fibroblasts with TNF-α. Moreover, BAPTA-AM 
also effectively blocked the repression of Dbp. On the other hand ethylene glycol 
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tetraacetic acid (EGTA) which chelates extracellular calcium and thereby inhibits 
influx of extracellular calcium, had only minor effects (Fig. 6A). Given these results, 
we find TNF-α acting on clock gene expression by modulation of intracellular calcium. 
In the attempt to elucidate the implication of further TNF-α signaling enzymes, we 
tested several kinase and phoshatase inhibitors. However, blocking the protein 
phosphatases (PP) 1 and PP2a or the kinases phosphoinositide-3-kinase, extracellular 
signal regulated kinase I and II, or calcium/calmodulin dependent kinase II had no 
influence on clock gene regulation by TNF-α. Solely, the inhibition of the MAPK p38 
was able to prevent the Per1 peak (Fig. 6B). However Dbp expression inhibition was 
not affected. 
Taken together, the data suggests that Per1 induction by TNF-α is dependent on 
inatracellular calcium and p38 signaling 
 
 
 
Fig. 6: The inhibition of Dbp is mediated by intracellular Ca2+ and the induction of Per1 is 
mediated by intracellular Ca2+ and p38 MAPK. (A) Effect of the intracellular calcium chelator 
BAPTA-AM on Per1 induction and Dbp inhibition by TNF-α. NIH 3T3 were treated with EGTA (1 µM) or 
BAPTA-AM (30 µM) 30 min before a 1 h stimulation with 10 ng/ml TNF-α. Expression of untreated 
samples corresponds to 1. Shown is the mean + SD; n=3-5 in triplicates; (B) Effect of p38 MAPK 
inhibition on the Per1 peak induced by TNF-α. NIH 3T3 were treated with SB203580 (10 µM) 30 min 
before a 1 h stimulation with 10 ng/ml TNF-α. Expression of untreated samples corresponds to 1. 
Shown is the mean + SD; n=4 in triplicates. For A and B we used paired samples t-test. *, p ≤ 0.05. 
 
 
Chromatin remodeling defines clock gene regulations 
 
To analyze the chromatin remodeling on the Dbp gene after TNF-α stimulation, we 
performed chromatin immunoprecipitation (ChIP) assays against acetylated histone 
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H3. There is clearly less acetylated histone H3 at the Dbp E-box 857 corresponding 
to the less activity in gene transcription. Therefore, we aimed to block deacetylation 
by using Trichostatin A (TSA) (HDAC 2 und 3) or splitomicin (HDAC 1). We did not 
find any significant effects on the inhibition of Dbp by TNF-α using TSA or 
splitomicin. These results suggest that active deacetylation is not important for 
blocking gene transcription of clock genes. 
 
 
Fig. 7: Less acetylated histone H3 at the Dbp E-box 857 corresponds to reduced 
expression, but active deacetylation is not involved in the inhibition of Dbp by TNF-α. (A) 
Less acetylated histones H3 at the Dbp E-box 857 in cells treated with TNF-α assayed by ChIP. NIH 
3T3 fibroblasts were synchronized by a serum shock and stimulated with 10 ng/ml TNF-α in serum-
free medium. After 24 h, at the peak of Dbp gene expression, chromatin was isolated and subjected 
to ChIP assay. Shown is the relative binding of acetylated histones compared to unstimulated cells. 
n=3 in duplicates or triplicates. (B) Trichostatin A and splitomicin have no effect on the inhibition of 
Dbp by TNF-α. After a 6 h or overnight pretreatment with TSA (10 ng/ml) or splitomicin (120 µM) NIH 
3T3 fibroblasts were stimulated with 10 ng/ml TNF-α for 3 h. 1 is the expression level in mock treated 
cells. Shown is the mean + SD; n=3 for TSA, n=2 for splitomicin, both in triplicates; For A and B we 
used paired samples t-test. *, p ≤ 0.05. 
 
 
Discussion 
The biology of circadian rhythms in mammals is dependent on the appropriate 
function of the molecular clock within all cells of the body. The activation of the 
immune system parallels the deregulation of circadian functions during the acute 
phase of infectious and autoimmune diseases; it is therefore intriguing to speculate 
that this may be linked to the sickness behavior syndrome. Recently, TNF-α was 
found to impair locomotor activity in mice and to impair E-box driven clock gene 
expression (6). Fibroblasts treated for 24 h with TNF-α respond with a decrease of E-
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box mediated transcription of Dbp, Tef and Hlf and of Period 1-3. The data on the 
effect of TNF-α on fibroblasts presented here, show that TNF-α treatment for only 1 
h induces Per1. This effect was not associated with synchronization of the fibroblasts 
(data not shown), although a striking characteristic of the synchronization of cells is 
the induction of the clock gene Per1 mRNA and protein. This may be a necessary 
event for the induction of circadian gene expression, but it is probably not sufficient 
as shown for epidermal growth factor which strongly induces Per1 but still does not 
induce circadian gene expression (18).  
Surprisingly, we found that besides Per1, TNF-α can also transiently induce other 
negative elements of the clock such as Per2, Cry1 and Dec1. Because blockade of 
de-novo protein synthesis partially reverses Dbp inhibition, the increase in negative 
regulators could be partially responsible for TNF-α mediated impairment of Dbp 
expression. However, when assaying Per1, Per2, and Dec1 deficient cells, we have 
not found direct evidence for this hypothesis. Dec1 and Dec2 have been reported to 
be regulated by several cytokines and Dec1 is also induced by TNF-α in our in-vitro 
setting (19). Even though we did not analyze the effect of Cry, there is indirect 
evidence that also Cry is not responsible for TNF-α induced downregulation of Dbp 
expression, because the heterodimerization of CRY:PER proteins should also be 
impaired in our Per deficient fibroblasts. Furthermore the induction of Cry1 
expression appears fairly late when Dbp is already strongly inhibited. These data 
strongly suggest that neither Per1 and Per2, nor Dec1 and Cry1 are involved in Dbp 
repression. However, it still cannot be excluded that in Per1/Per2 double knockout 
cells Dec1 may lead to suppression of Dbp expression. Moreover, Per1 and Per2 may 
compensate for Dec1 deletion. 
TNF-α mediates its function by TNF receptors, TNFR1 and TNFR2. By using knockout 
fibroblasts, we observed that signaling via TNFR1 is sufficient to detect the early 
Per1 upregulation and early as well as late Dbp downregulation. There are evidences 
that soluble murine TNF-α has a higher affinity to TNFR1, and that ligand binding to 
TNFR2 is short and unstable (20). We detected no cell activation by measuring IL-6 
expression in TNFR1 deficient cells, still expressing TNFR2 on the surface, indeed 
emphasizing the higher relation of soluble TNF-α to TNFR1. We were surprised to 
find that the main TNF-α signaling pathways, comprising the NF-κB, JNK and 
caspase pathways are not responsible for clock gene regulation and that rather a 
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“side” pathway, the Ca2+ signaling, is mediating the E-box dependent effect of TNF-
α. A role for calcium signaling in circadian clocks has been extensively studied in the 
SCN. There it has been shown that not only Ca2+ can regulate clock gene expression 
but also that the circadian clock controls intracellular Ca2+ rhythms (21-23). Ca2+ 
influx is an initial cellular event in response to glutamate stimulation by the 
retinohypothalamic tract in the SCN, thereby disturbing the intracellular Ca2+ 
homeostasis. It has therefore been proposed to be one of the messengers conveying 
environmental time signals to the endogenous clock. The Per1 gene is first induced 
before it is inhibited at later time points. This induction is dependent on the 
activation of p38 and intracellular Ca2+. These to messengers are well described to 
lead to a phosphorylation of the cAMP responsive element (CRE) binding protein 
(CREB). In the SCN, the binding of CREB to CRE sites in the Per1 promoter in turn 
induces gene expression (24, 25). Although it remains to be further investigated, we 
think that Per1 expression is first induced through its CRE sites and thereafter 
inhibited through its E-box sequences. Here, we report the novel finding of clock 
gene expression regulation by Ca2+ signaling outside of the SCN. It therefore seems 
that Ca2+ plays a central role in the periphery as well. We think that analogue to the 
SCN, Ca2+ could also be considered as a physiological sensor in the periphery, 
transmitting immunological changes to the molecular clock and thereby coordinating 
the special needs to specific time windows. 
 
 
 
Materials and Methods 
Cell lines, cytokines and chemicals 
 
Murine fibroblast cells, NIH 3T3 (CRL-1658) were obtained by the American Type 
Culture Collection; human keratinocyte cells, HaCaT, knockout for Dec1, were 
generously provided by B. Vogelstein (9). Embryos of wt (C57Bl/6), TNFR1-/-, 
TNFR2-/- mice were used at day 12 of gestation (E12). The liver and heads were 
removed, the remaining tissue was digested with 0.25% trypsin-EDTA in DMEM for 
30 min at room temperature. The dissociated cells were plated in DMEM containing 
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20% FCS. They were split 1:4 until they reached passage 10. Cells were used within 
passage 10 - 30. p65-/- and control MEFs were generously provided by M. Hottiger 
(University of Zürich) (10). mPer1-/- and mPer2-/- single knockout and mPer1-/-
;mPer2-/- double knockout MEFs were generously provided by U. Albrecht (University 
of Fribourg) (11). 
Recombinant murine (rm) TNF-α, was purchased from Peprotech (London, U.K.); 
BAPTA-AM, Cycloheximide, EGTA, splitomicin, actinomycin D from Sigma (ST.Louis, 
MO, USA); SB203580 from EMD chemicals (Darmstadt, Germany) and Trichostatin A 
from InvivoGen (St. Diego, USA). 
 
Cell culture and stimulation  
 
NIH 3T3 fibroblasts were grown in DMEM (Gibco, Basel, Switzerland) supplemented 
with 10% FBS (PAA Laboratories, Pasching, Austria) and Glutamax (Gibco). For 
stimulation cells were grown to confluency and then medium was replaced with 
serum-free DMEM/Glutamax with or without TNF-α. After stimulation, tissue culture 
plates were washed once with ice-cold PBS solution and kept at –70 °C until the 
extraction of whole-cell RNA. 
 
FACS staining 
 
Cells were trypsinized and resuspended in FACS buffer (PBS, 0.5% BSA, 0.02% 
Sodium azide) at 4°C. Antibody staining was performed with 1:100 isotype-ab 
(553951, BD Pharmingen), TNFR1-ab (559915, BD), TNFR2-ab (559916, BD) 
followed by 1:200 secondary biotinylated Goat anti-Hamster antibody (127-065-160, 
jackson immunoresearch), then with 1:200 SAV-APC (554067, BD). Staining was 
analyzed with FACS analyzer (Partec, Germany). Curves were smoothed for better 
visualization of the results. 
 
 
Western blot 
 
Cells were lysed in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA 
1 mM PMSF, 1% NP40, 10% glycerol, protease inhibitors) and protein concentration 
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was measured using BCA (Pierce). 20 µg of total proteins were run with Tris-Tricine 
SDS-PAGE (12). Western blotting was performed at 4°C and blot was blocked with 
5% milk powder (Biorad) in TBS-T overnight. Staining was performed with 1:5000 
p65 antibody (sc-372 X, santacruz), and 1:100'000 goat anti-mouse-HRP ab (jackson 
immunoresearch), and ECLplus (Amersham) reaction. Same blots were re-stained 
with 1:2000 β-tubulin ab (Abcam). 
 
RNA isolation and gene expression analysis 
 
Whole-cell RNA from cultured cells was extracted using TRIzol (Invitrogen) or 
peqGOLD RNAPure (peqLab) according to the manufacturer’s instructions. 
Subsequently, RNA was reverse-transcribed using random hexamers (Roche) and M-
MuLV reverse transcriptase (Applied biosystems). The cDNA equivalent to 20 ng of 
total RNA was PCR-amplified in an ABI PRISM HT7900 detection system (PE-Applied 
Biosystems) using the TaqMan Universal PCR Master Mix (Applied Biosystems) and 
quantified as follows. Primers and probes for Taqman analysis were either purchased 
from Applied Biosystems or purchased from Microsynth, Balgach Switzerland as 
described in detail in SI table 1. The relative levels of each RNA were calculated by 
the 2-∆∆Ct method (Ct standing for the cycle number at which the signal reaches the 
threshold of detection); Gapdh mRNA was used as a housekeeping gene. Each Ct 
value used for these calculations is the mean of two duplicates of the same reaction. 
Relative RNA levels are expressed as x-fold variations compared to untreated. 
 
Chromatin immunoprecipitations  
 
All steps were performed at 4 °C or on ice. About 1 x107 cells per condition were 
used as starting material. Cells were fixed for 5 min at 37 °C with 1x PBS containing 
1% formaldehyde. Subsequently, cells were washed twice with ice-cold 1x PBS and 
scraped in Glycin buffer (125 mM Glycine; 100 mM Tris, pH 9.4; 10 mM DTT). To 
stop fixation, cells were kept on ice for 15 min. After a short spin of 1,5 min, 2000 g, 
pelleted cells were resuspended in buffer I (0.25% Triton x-100; 10 mM EDTA; 1 mM 
EGTA; 10 mM HEPES, pH 6.5) by vortexing. Cells were pelleted at 2000 g, 5 min and 
carefully resuspended in buffer II (200 mM NaCl; 1 mM EDTA; 1 mM EGTA; 10 mM 
HEPES, pH 6.5). After another centrifugation for 5 min, 2000 g, nuclei were carefully 
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resuspended in 190 µl nuclei resuspension buffer at RT (165 mM NaCl; 2.2 mM 
EDTA; 22 mM Tris-HCl, pH 8). After addition of 10 µl 20% SDS, nuclei were 
submitted to 5 x 1 min sonication steps with 30 sec pauses in between using the 
Bioruptor™ sonication machine (Diagenode, Liège, Belgium). The fragmented cross-
linked chromatin was then diluted tenfold in dilution buffer (1.1% Triton X-100; 2 
mM EDTA; 150 mM NaCl; 20 mM Tris-HCl, pH 8). 100 µl chromatin was used as 
starting material for DNA quantification experiments and 1 µl was used as input 
measurement. Immunoprecipitated DNA fragments captured by protein A–
agarose/salmon sperm DNA (Millipore, Billerica, MA, USA) were washed sequentially 
with 500ml TSE I (20 mM Tris-HCl, pH 8; 150 mM NaCl; 2 mM EDTA; 0.1% SDS; 1% 
TX-100), TSE II (20 mM Tris-HCl, pH 8; 500 mM NaCl; 2 mM EDTA; 0.1% SDS; 1% 
TX-100), buffer III (0.25 M LiCl; 1% NP-40; 1% DOC; 1 mM EDTA; 10 mM Tris-HCl, 
pH 8) and TE buffer (10 mM Tris-HCl, pH 8; 1 mM EDTA) and the cross-links, 
including inputs, were reversed overnight at 65 °C in 20 mM Tris-HCl, pH 7.5; 150 
mM NaCl; 2 mM EDTA; 1% SDS. DNA fragments were recovered using the DNA 
columns from the Qiagen MiniPrep kit according to the manufacturers protocol. Two 
microliters of each reaction were directly used in 10 µl real-time PCR reactions using 
a 7900 HT machine (Applied Biosystems). The amount of DNA was quantified as 
described above. Each value was normalized to the corresponding input. Three 
independent experiments were done in duplicate or triplicate. The primers and 
Taqman probes used are listed in table 1. The antibody against acetylated histone H3 
was purchased from Millipore.  
 
Nascent transcript assay  
 
All steps were performed on ice or at 4 °C. 2 x107 cells were scraped and washed 
twice with PBS, resuspended in 400 µl of HB 0.3 M sucrose (10% glycerol, 0.3 M 
sucrose, 60 mM KCl, 15 mM NaCl, 15 mM HEPES, pH 7.9, 0.5 mM EDTA, 0.15 mM 
spermine, 0.5 mM spermine, 0.5 mM PMSF, 1 mM DTT) and lysed by the addition of 
400 µl HB 0.3 M sucrose containing 0.8% NP-40. After a 10 min incubation, nuclei 
were pelleted through a 1.2 ml cushion of HB 0.9 M sucrose by a 10 min 
centrifugation at 1500 g and resupended in 500 µl of nuclear suspension buffer (75 
mM NaCl, 20 mM Tris-HCl, pH 7.9, 0.5 mM EDTA, 0.125 mM PMSF, 0.85 mM DTT, 
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50% glycerol, 100 mg/ml tRNA). Nuclei were lysed on ice for 10 min in 2400ml 
nuclear lysis buffer (0.3 M NaCl, 20 mM HEPES, pH 7.6, 0.2 mM EDTA, 7.5 mM 
MgCl2, 1 M urea, 1 mM DTT, 1 % NP-40 and 100 mg/ml tRNA). Chromatin was 
pelleted by 10 min at 15,000 g in a microfuge, resuspended in 500 ml of chromatin 
suspension buffer (50 mM Na acetate, pH 5, 50 mM NaCl, 0.5% SDS, 100 mg/ml 
tRNA), extracted three times with hot phenol mix (acid phenol saturated with water; 
5 mM Na acetate, pH 5; 5 mM NaCl) at 65 °C. After addition of NaCl to a final 
concentration of 150 mM, nucleic acids were precipitated with ethanol, resuspended 
in 50 ml 10 mM Tris-HCl, pH 7.5, and treated with RNase-free DNase to eliminate 
genomic DNA. Nascent transcripts were then extracted with phenol-chloroform, 
precipitated and resuspended in 30 µl of 10 mM Tris-HCl, pH 7.5. 10 µg were used 
for reverse transcription and real-time PCR, which were performed as described 
above. Results were corrected for cDNA input by amplifying nascent gapdh 
transcripts. The primers and Taqman probes used are listed in table 1. 
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Supporting information 
 
 
Fig. S1: The reduced levels of Dbp mRNA in NIH 3T3 fibroblasts is not due to an 
accelerated mRNA degradation. (A) Dbp mRNA degradation is very rapid. Cells were treated with 
1 µg/ml Act D with or without 10 ng/ml TNF-α and collected after 30 or 75 min for mRNA 
quantification. Values are relative to untreated samples collected at time point 60 min. n=1 in 
triplicates. (B) Cells were stimulated with 10 ng/ml TNF-α overnight or left untreated. RNA was 
prepared for nascent transcripts analysis. n=1 with one sample per condition. 
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Fig. S2: Caspases are not involved in Per1 and Dbp regulations. NIH 3T3 cells were treated 
with 10 ng/ml TNF-α with or without 50µM Z-VAD-FMK simultaneously for 1 h. Values are relative to 
samples without TNF-α stimulation. Shown is one experiment done in triplicates. 
 
 
 
 
 
 
 
Table S1. Sequences for primers and probes. 
 
Assay Gene FP Probe RP
nascent transcripts clock GGGATGGGTGGGTAATGTCA CAGAGAGTATTGGTACACAGGACAGCGTAGCA ACTACAGTTCTTAGGCGCACAGATG
dbp CTACGTTCCCGGATCCTACAC CCCATTCCCCAAGTGGATGGTGTT GATCCCGATATTCTCTTCTGCAA
per1 ACCAGCCATTCCGCCTAAC CTGCCTACTCATTGCCGAGCG CCTAGCCTATCCACCTTCATAACC
ChIP Dbp 857 ATGCTCACACGGTGCAGACA CCTAGTTTCCATGTGACCCTGCGAGG CTGCTCAGGCACATTCCTCAT
PCR tnfr1 ACCAAGTGCCACAAAGGAAC CACGCACTGGAAGTGTGTCT
tnfr2 TACCAAGGGTGGCATCTCTC TCCTGGGATTTCTCATCAGG
real time PCR dbp GCGAGAAGTGCAAAATTGGC CGCGCGCCTGTGTCCCTTG CGGGAGGCTCCTATAGTCTGG
clock TTGCTCCACGGGAATCCTT ACACAGCTCATCCTCTCTGCTGCCTTTC GGAGGGAAAGTGCTCTGTTGTAG
cry1 CTGGCGTGGAAGTCATCGT CGCATTTCACATACACTGTATGACCTGGACA CTGTCCGCCATTGAGTTCTATG
cry2 TGTCCCTTCCTGTGTGGAAGA CAGTCACCCTGTGGCAGAGCCTGG GCTCCCAGCTTGGCTTGA
SYBR green per1 1A TTACTCTGGAGCCGTCGAACTTGT AGGACGAAACAGGGAAGGTGAAGA
per1 1B GAACGGCCAGGTGTCGTGATTAAA AGGACGAAACAGGGAAGGTGAAGA
Pre-developed taqman assays (Applied biosystems)
real time PCR gapdh 4352339E
per1 Mm00501813_m1
per2 Mm00478113_m1
per3 Mm00478120_m1
dec1 Mm00478593_m1
dec2 Mm00470512_m1
IL-6 Mm00446190_m1
human gapdh 0-0702011
human dbp Hs00609747_m1
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5. GENERAL DISCUSSION AND OUTLOOK 
We found that the pro-inflammatory cytokine TNF-α impairs the molecular circadian 
clock in vivo  and in vitro. By applying the cytokine constantly to mice with the use of  
subcutaneously implanted osmotic minipumps, we could observe a decrease in the 
mRNA levels of several central clock genes, such as Per1, Per2, Per3, and clock 
output genes, such as Dbp, Tef and Hlf in the liver. The expression of the core clock 
transcription factors Clock and Bmal1 remained unchanged. In addition, these mice 
showed less locomotor activity and an increase in rest periods indicating that these 
mice may suffer from fatigue. In NIH 3T3 fibroblasts, which are used as a model to 
study circadian rhythms, we assessed clock gene expression in the presence of 
recombinant TNF-α. In line with the results from the in vivo experiments, the three 
Period clock genes and the three PAR-bZIP output genes were also affected in vitro. 
We therefore decided to continue using this in vitro model for further analysis of the 
underlying mechanisms. We noticed that genes bearing an E-box in their promoter 
seem to be the ones targeted by TNF-α, whereas Clock and Bmal1 that are devoid of 
E-boxes are unaffected. To confirm the hypothesis that TNF-α acts indeed via these 
E-boxes we used luciferase reporter constructs, thereby showing that luciferase 
controlled by E-box elements is inhibited in the presence of the cytokine. When these 
E-boxes were mutated Dbp was de-repressed. Complementary to that, when 
luciferase is driven by the Bmal1 promoter no change could be observed after 
addition of TNF-α. Interestingly, the total inhibition is less dramatic in the luciferase 
assays compared to RNA expression analysis. This could be an indication for a 
supplementary inhibition mechanism independent of E-boxes. 
Several scenarios can be envisaged that could lead to an E-box dependent down-
regulation. 
1) Induction of an inhibitor that would either bind directly to the E-box thereby 
preventing CLOCK/BMAL1 binding or bind to the CLOCK/BMAL1 complex and disable 
transactivation. This inhibitor may be synthesized upon TNF-α stimulation or could 
also already be present in the cytoplasm and would be shuttled to the nucleus after 
stimulation with TNF-α. Experiments in which we used the translation inhibitor 
cycloheximid would support both possibilities. After one hour stimulation, Dbp 
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expression was partly de-repressed in the presence of the inhibitor. We think that 
the rapid inhibition can take place without the need of a newly synthesized protein 
and that at later time points an inhibitory protein needs to be produced to emphasize 
the dampening. The early and late effect may be mediated by the same promoter 
elements but could also act on two different regions again supporting the notion that 
two different inhibition mechanisms could be implicated. 
The most obvious possible inhibitors would be members of the negative limb of the 
molecular clock. Although MEFs with single Period gene knock-out had little but 
significant effect on Dbp expression, MEFs lacking both genes still showed a 
comparable downregulation to wild-type MEFs.  
Since Dec1 and Dec2 have been reported to be regulated by several cytokines and 
because Dec1 is also induced by TNF-α in our in vitro setting, it was an additional 
strong candidate inhibitor (138). However, we could not find an implication for this 
gene.  
The induction of Cry1 expression appears fairly late when Dbp is already strongly 
inhibited, nonetheless, it would still be worth investigating for a role of this gene in 
the inhibitory mechanism. Since the degradation of CRY1 could be inhibited, the 
protein would accumulate and inhibit CLOCK/BMAL1 complexes. The same scenario 
could apply to CRY2.  
As mentioned above, only the localization of the inhibitor could be altered by TNF-α. 
Therefore, it would be a possibility to analyze the localization of the negative 
regulators by Western blot or Immunfluorescence imaging.  In addition, to define 
whether the import of one of these negative regulators is an important event in TNF-
α mediated clock gene expression dampening, it would be elegant to prevent the 
translocation into the nucleus. Overexpression of negative regulator proteins that are 
mutated in their nuclear import signal sequences would prevent nuclear import in a 
dominant negative way. 
2) Posttranslational modifications of CLOCK and/or BMAL1 would lead to differential 
stability, localization or DNA affinity of the proteins (139).  It will be important to 
analyze the CLOCK and BMAL1 protein levels as well as their modifications and 
localization. After separating the nuclear from cytoplasmic protein fraction the 
amount of CLOCK and BMAL1 could be quantified by Western blot. An accumulation 
of BMAL1 for instance would lead to BMAL1 homodimer formation which are not 
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transcriptionally active. On the other hand, a decrease of CLOCK protein could 
approach the phenotype of Clock knock-out mice. These animals show a decreased 
expression of Clock and clock controlled genes, such as Per1, Rev-erbα and Dbp in 
the liver, hence, a similar picture to TNF-α treated mice (140).  
Western blot analysis could additionally reveal possible modifications evoked by the 
cytokine. Phosphorylation residues make the protein run slower on a gel thereby the 
native and modified proteins are uncovered. Immunoprecipitation of the proteins and 
subsequent analysis by mass spectrometry could deliver further details like the 
localization of the phosphorylated residues. This is important as the outcome in 
activity may be different (58, 67).  
Differential DNA binding activities of the two core proteins CLOCK and BMAL1 could 
be analyzed by chromatin immunoprecipitation. A scenario where CLOCK and BMAL1 
show reduced DNA binding activity in the presence of TNF-α would speak for an 
inhibitor displacing the heterodimeric transcription factor. If there is no change in 
DNA binding, the transactivation ability may rather be altered by posttranslational 
modifications.  
Although reports about an activation of HATs by TNF-α are missing, it is also 
conceivable that TNF-α signaling could lead to an enhanced acetylation of BMAL1 
and/or PER2. Both modifications would lead to a dampening of E-box dependent 
transcription.  
Finally, due to the impact of BMAL1 sumoylation on its activity, it would be 
interesting to look for sumo modification after TNF-α treatment. This is of great 
interest because TNF-α signaling has already been implicated in desumoylation 
processes. The group of Wan Ming showed that upon TNF-α stimulation of resting 
endothelial cells, the nuclear protein homeobox-interacting protein kinase 3 (HIPK-3) 
is desumoylated by the SUMO-1 specific protease SENP1, thus targeting HIPK-3 to 
the cytoplasm (141, 142). Such a scenario would also be feasible for BMAL1, which 
has been shown to undergo SUMO modifications. 
3) Loss of histone acetylation would lead to a reduction in transcriptional activity. We 
could not find an implication of HDACs in the inhibitor mechanism but still observed 
reduced levels of acetylated histones in the presence of TNF-α. This suggests rather 
a passive deacetylation process. Histones are supposedly no longer acetylated as a 
consequence of a lack of gene expression activity or a reduced activity of HATs, such 
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as CLOCK and/or p300. In parallel, histones are regularly exchanged thereby 
resulting in a lower concentration of acetylated histones over time (143). 
 
We also observed that TNF-α only dampens the peak expression thereby leaving the 
period length intact. Additionally the effect of the cytokine on Dbp expression is very 
direct, rapid and transient as it can be reversed after removal of the cytokine. In 
contrast the inhibition of the Period genes is delayed. This let us hypothesize that 
DBP may play a role in Period down regulation. Indeed, DBP binding elements have 
been found in the Per1 promoter and DBP together with CLOCK and BMAL1 has been 
described to cooperatively induce Per1 transcription. A luciferase construct containing 
1.3 Kbp of the Per1 promoter was shown to be induced up to three times more when 
DBP was co-transfected in addition to CLOCK and BMAL1 (144). Furthermore the 
phase of Dbp expression in vivo is slightly earlier to Per1. In this context the rapid 
down regulation of Dbp would passively lead to an inhibition of Per1 through the lack 
of DBP transcriptional co-activator. Due to their homology to Per1, it is thinkable that 
Per2 and Per3 are regulated similarly. It is possible to test this hypothesis by 
overexpressing DBP.  A construct coding for the Dbp mRNA under the control of a 
promoter that is insensitive to TNF-α could be expressed in fibroblasts. DBP quantity 
would no longer be affected by TNF-α treatment and Per1 inhibition, if regulated by 
DBP, would not occur anymore. 
 
An important result was that the effect of TNF-α can be mediated by the TNFR1. 
This finding may explain the ubiquitous ability of TNF-α to downregulate clock gene 
expression, as TNFR1 is known to be expressed on almost all cell types (123). 
Indeed, we analyzed clock gene expression in vivo in many different tissues of TNF-α 
infused mice and always observed an inhibition of most E-box controlled clock genes. 
In vitro, we not only measured a Dbp inhibition in NIH 3T3 cells but also  in MEFs, 
human keratinocytes, CAD neurons and the SCN cell line SCN2.2 (data not shown).  
 
Since TNF-α binding to its receptors leads to the activation of a broad range of 
kinases, we wanted to elucidate which kinase could be involved in the 
downregulation mechanism. We therefore used inhibitors against kinases either 
known to be part of the TNF-α signaling cascade or to be involved in clock gene 
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expression regulation. The only inhibitor interfering with TNF-α mediated clock gene 
regulation was an inhibitor against the MAPK p38. Inhibiting this kinase in fibroblasts 
abolishes Per1 induction by TNF-α. Interestingly inhibitors interfering with the main 
TNF-α signaling pathways, comprising the NF-κB, JNK and caspase pathways were 
not able to de-repress Dbp  expression or abolish the Per1 peak. 
 
The common pathway leading to Dbp repression and early Per1 induction seems to 
be the intracellular Ca2+ pathway.  
Calcium is a widely used messenger that can control several different cellular 
processes the two main ones being exocytosis and gene transcription. Calcium can 
enter the cytosol from two different compartments, which are the intracellular 
organelles where the endoplasmatic reticulum (ER) is the major source, and the 
extracellular space. Ca2+ release from the ER by extracellular stimuli can be provoked 
by the generation of several different second messengers that target Ca2+ channels. 
The most widely used is inositol 1,4,5-triphosphate (IP3) that activates Ca2+ stores 
by binding to its receptor IP3R. A second Ca2+ sensitive channel known to release 
Ca2+ stores from the ER is the ryanodine receptor (RYR). This receptor can be 
activated by cyclic adenosine diphosphate-ribose (cADPR). The released Ca2+ in turn 
can directly activate both channels and further amplify the signal (145). 
Although the contribution of cytosolic Ca2+ signaling in the regulation of circadian 
clock has been extensively studied in a variety of organisms no commonalities in the 
Ca2+-mediated signaling process have been described among the various circadian 
clock systems (146). Most studies in mammals were performed in the SCN. There it 
has been shown that not only Ca2+ can regulate clock gene expression but also that 
the circadian clock controls intracellular Ca2+ rhythms (147-149). An exact 
mechanism is still missing but it is hypothesized that cADPR is an intermediate 
messenger (146). Furthermore a central role for cAMP has been confirmed recently 
(149). Ca2+ influx is an initial cellular event in response to glutamate stimulation by 
the RHT in the SCN, thereby disturbing the intracellular Ca2+ homeostasis. It has 
therefore be proposed to be one of the messengers conveying environmental time 
signals to the endogenous clock, where the RYR dependent Ca2+ influx is thought to 
amplify the signal (150, 151). Ca2+, in turn, phosphorylates cAMP response element-
binding protein through activating CaMKII and/or MAPK (152, 153). Subsequently 
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CREB binds to the CRE elements in the Per promoter and induces gene transcription. 
In our setting it is possible that p38 is activated by Ca2+ and then phosphorylates 
CREB and induces Per1 via its CRE sites. Besides Per1, only CLOCK has been 
reported to be regulated by Ca2+. Phosphorylation of CLOCK is mediated by the Ca2+ 
dependent PKC pathway leading to its translocation to the nucleus (68). The 
expression of further clock genes has not been analyzed so far. We are the first to 
report clock gene expression regulation by Ca2+ signaling outside of the SCN. How 
the repression is achieved is unclear but one possibility could involve cAMP and/or 
cADPR increase by TNF-α. 
TNF-α as well as other pro-inflammatory cytokines have been shown to increase 
intracellular Ca2+ via an increase in cADPR in airway smooth muscle cells (SMC) 
(154). In these cells sarcoplasmic Ca2+ can be released through IP3R channels as 
well as RYR channels. There is strong evidence that the cell surface protein CD38 is 
responsible for the TNF-α mediated increase in cADPR. The up-regulation of CD38 
mRNA, involving MAPK and transcription factors NF-κB and AP-1, enhances the 
production of cADPR and thereby Ca2+ release. Other cytokines, like IL-13, IL-1β and 
IFN-γ were also shown to induce CD38 transcription although in a less extensive way. 
With all these cytokines the intracellular Ca2+ release in SMC could be inhibited with 
the addition of a cADPR agonist, 8-bromo-cADPR (155, 156). It is strongly 
conceivable that a similar mechanism applies to NIH 3T3 fibroblasts and that the 
effect of TNF-α on clock genes may partly be mediated by CD38. If indeed TNF-α 
acts via these Ca2+ stores then clock gene expression would be de-repressed in the 
presence of 8-bromo cADPR. 
On the other hand, TNF-α can also directly activate several kinases that have been 
implicated in IP3R dependent Ca2+ release (145, 157). Inhibition of 
Sphingomyelinase, PKA, PKC or PLC may also show a de-repression in clock gene 
expression. 
 
A speculative but possible Ca2+ dependent  inhibition mechanism could be that TNF-
α first rapidly induces Ca2+ release via IP3R. In parallel, via the NF-κB and AP-1 
pathway, CD38 is induced and cADPR synthesized. cADPR then binds to RYR 
enhancing the Ca2+ release from intracellular stores (Figure 2). This pathway is much 
slower as it comprises the synthesis of a new protein. Our results support such a 
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model in many aspects. A rapid Ca2+ release first induces Per1 via its CRE sites and 
inhibits Dbp. Additional Ca2+ is then also capable of repressing other E-box 
dependent clock genes such as the period genes. This would mean that Dbp is more 
sensitive to calcium changes than period genes are. The reason why we were not 
able to show an implication of NF-κB and/or AP-1 could be because of the short 
stimulation times we used. According to this model NF-κB and AP-1 would only be 
involved at later time points. It may also be worth blocking both pathways 
simultaneously. As mentioned above experiments with cycloheximide, showing a 
partial de-repression of Dbp after 1 hour stimulation, support the idea of a two phase 
model, where a long term inhibition needs the synthesis of a protein 
It will be interesting to monitor the intracellular Ca2+, cADPR and cAMP levels in the 
NIH 3T3 fibroblasts in the presence or absence of TNF-α.  
A further interesting subject of investigation would be the regulation of circadian 
gene transcription by Ca2+. So far, as mentioned above, only Ca2+ dependent Per1 
induction via CREB phosphorylation has been described. We examined the 
involvement of the calcium/calmodulin kinase II in the inhibitory mechanism but 
could not find an implication. Similarly a role for the calcium/calcineurin sensitive 
phosphatase PP1 could be excluded (data not shown). A third well-known calcium 
dependent enzyme is calcineurin. An implication of this phosphatase remains to be 
elucidated. 
Of particular interest are the calcium sensors S-100 and calmodulin. These two 
proteins, when loaded with Ca2+, have been reported to bind to bHLH proteins, 
thereby blocking their DNA binding and/or prevent their post-translational 
modifications (158-161). Although reports about interaction of these sensors with the 
bHLH proteins CLOCK and BMAL1 are missing, it is conceivable that the interaction of 
CLOCK/BMAL1 heterodimers with E-boxes is abolished through the binding of such a 
calcium sensing protein after TNF-α stimulation. It would therefore be interesting to 
analyze CLOCK and BMAL1 binding to E-boxes by ChIP assay and an interaction of 
these two proteins with calmodulin or S-100 in the presence of TNF-α by 
immunoprecipitation and subsequent Western blot analysis.  
Another calcium sensor, downstream responsive element antagonist modulator 
(DREAM), has been shown to inhibit gene transcription in a Ca2+ dependent manner 
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by binding to DRE sites (162). It is therefore also a candidate that may be involved in 
clock gene inhibition and needs to be examined. 
It is possible that S-100 and calmodulin account for the E-box mediated inhibition, 
whereas DREAM may provide further repression independent of the E-boxes. 
 
 
 
 
Fig.2: TNF-α signaling leads to alterations in clock gene expression: a possible model 
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As the central and peripheral clock mechanisms are very similar, if not identical, it is 
not surprising that the Ca2+ signaling also plays a central role in clock gene 
regulation in the periphery. Although extracellular Ca2+ influx may not be as relevant 
in the periphery as in the SCN neurons, intracellular Ca2+ release possibly plays a 
crucial role in the regulation of clock gene expression. We propose that analogue to 
the SCN, Ca2+ could also be considered as a physiological sensor in the periphery, 
transmitting immunological and metabolic changes to the molecular clock and 
thereby coordinating the special needs to specific time windows. We can imagine it 
being very reasonable to down regulate the clock during an infection. In that way, 
since cell cycle is closely related to the circadian system, immune cell proliferation, 
which must occur immediately and frequently, is independent of circadian time 
windows (163). Similarly, the production of immunological important proteins would 
be time independent as well. Thus, temporary dampening of the clock may 
contribute to a fast and effective immune response. 
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7. ABBREVIATIONS 
 
ASK  apoptosis stimulated kinase 
AP  activator protein 
bHLH  basic helix-loop-helix 
Bmal1  brain and muscle Arnt-like protein 1 
βTrCP  β-transducin repeat containing protein 
bZip  basic leucine zipper 
cADPR cyclic adenosine diphosphate-ribose 
cAMP  cyclic adenosine monophosphate 
CCG  clock-controlled gene 
ChIP  chromatin immunoprecipitation 
CIPC  clock interacting protein circadian 
CK  casein kinase  
CLC  cardiotrophin-like cytokine 
Clock  circadian locomoter output cycles kaput 
CRE  cAMP response element 
CREB  cAMP response element binding protein 
Cry  cryptochrome 
Dec  differentiated embryo chondrocytes 
Dbp  D-site albumin promoter binding protein 
DD  death-domain 
DNA  deoxyribonucleic acid 
DMEM  Dulbecco's modified Eagle medium 
DREAM downstream responsive element antagonist modulator 
ER  endoplasmatic reticulum 
FASP  familial advanced sleep-phase syndrome 
FBS  fetal bovine serum 
GSK  glycogen synthase kinase 
HAT  histone acetyl transferase 
HDAC  histone deacetylase 
HIPK  homeobox-interacting protein kinase 
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Hlf  hepatic leukemia factor 
IFN  interferon 
I-κB  inhibitor of κB 
IKK  inhibitor of NF-κB kinase 
IL  interleukin 
IP3  inositol 1,4,5-triphosphate 
JNK  c-Jun N-terminal kinase 
LD  light-dark cycle 
LDH  lactate dehydrogenase 
LPS  lipopolysaccharide 
LT  lymphotoxin 
MAPK  mitogen activated protein kinase 
MEKK  extracellular signal-regulated kinase kinase kinase 
NADP  nicotinamide adenine dinucleotide phosphate 
NEMO  NF-κB essential modulator 
NF-κB  nuclear factor kappa B 
NPAS2 neuronal PAS domain protein 2 
PAR  proline and acidic amino acid-rich 
PAS  Per-Arnt-Sim 
Pdxk  pyridoxal kinase 
Per  period 
PK  protein kinase 
PK2  prokineticin-2 
PLP  pyridoxal phosphate 
PMA  phorbol-12-myristate-13-acetate 
PP  protein phosphatase 
RIP  receptor-interacting protein 
ROR  retinoic acid receptor-related orphan receptor 
RYR  ryanodine receptor 
SAD  seasonal affective disorder 
SCF  SKP1-Cullin1-F-box protein 
SCN  suprachiasmatic nucleus 
SMC  smooth muscle cell 
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SNP  single nucleotide polymorphism 
Sirt  sirtuin 
SODD  silencer of death-domain 
Sumo  small ubiquitin related modifier 
TACE  TNF-α converting enzyme 
Tef  thyrotroph embryonic factor 
TGF-α  transforming growth factor alpha 
TNF-α  tumor necrosis factor alpha 
TNFR  TNF receptor 
TLR  Toll-like receptor 
TPA  12-O-Tetradecanoylphorbol-13-Acetat 
TRADD TNFR associated death domain 
TRAF  TNFR-associated factor 
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